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1.1 Distribution of malaria and P. falciparum  
 
1.1.1 Global distribution of malaria  
 
Four Plasmodium species can cause human malaria: P. falciparum, P. vivax, P. 
ovale and P. malariae. P. falciparum is the most pathogenic and the most prevalent 
of these species, especially in Africa. P. vivax is practically absent in this continent 
because of the absence of Duffy factor in black Africans. P. falciparum and P. vivax 
are prevalent in both Asia and South America. Malaria is transmitted by about 60 
different species of Anopheles mosquitoes, with different habitats and different 
efficiencies of transmission (1).  
Malaria is a global health problem, causing more than 300 million clinical  
 
Figure 1.1: Distribution of endemic malaria In Sub-Saharan Africa. Courtesy of 
MARA/ARMA (http://www.mara.org.za). The Malaria distribution model is described 
by Craig et al. (5).  
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cases and over a million deaths every year; most of these are children under five 
years old (2). Moreover, malaria is a poverty related disease. The poorest 20% of the 
world population represents 58% of all malaria cases (3). The vast majority of these 
cases, 90%, occur in Sub-Saharan Africa (4). The distribution of P. f. malaria in 
Africa is shown in Figure 1.1. The majority of malaria-exposed people live in regions 
where malaria is endemic and transmission intensity is high. On the fringes of 
endemic malaria regions, transmission intensity is low and epidemics of malaria may 
occur. Risk groups for malaria morbidity and mortality are children and pregnant 
women, particularly in endemic malaria regions.  
The field studies described in this thesis were performed in malaria-endemic 
regions of Cameroon and the Indonesian province of Papua, formerly Irian Jaya. 
 
 
1.1.2 Malaria in Cameroon 
 
Cameroon consists of 4 climate zones: Sahel along Lake Chad, Sudan savannah 
in the extreme northern region, Guinea savannah in the northern region and 
Adamoua, and the northern half of the north-west, and rain forest in the more 
southern regions (6). Malaria is endemic throughout Cameroon and perennial in 
approximately 80% of the country (Figure 1.2). Transmission and prevalence are 
reduced in the west and north-western regions, around Yaoundé and Mount 
Cameroon (Buea). Malaria prevalence is high in the deltas on the shore of the 
Atlantic Ocean near Douala and below Mundemba next to the Nigerian border. 
Intensity of malaria transmission ranges from 4 to 30 infectious bites per person per 
year (ibpy) in urban areas up to nearly 600 ibpy in rural Cameroon (7-9). Prevalence 
of P. falciparum may reach 75% in children under 10 years of age in high 
transmission areas (9). Studies described in this thesis have been conducted in the 
capital Yaoundé and rural Koundou. 
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Figure 1.2: Transmission in Cameroon (Yaoundé, Koundou), adapted from malaria 
transmission maps of the MARA/ARMA collaboration. The malaria seasonality 
models have been described by Snow et al. (10), Tanser et al. (11, 12) and by Craig 
et al. (1999). 
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1.1.3   Malaria in Indonesia 
 
Malaria has a very wide, uneven distribution in Indonesia. Plasmodium parasites 
are the least prevalent on Java, the island with the largest population of the 
archipelago and the highest population density. Prevalence of Plasmodium parasites 
on Java is high in certain centrally situated malaria foci, e.g. with 1% of all cases in 
the Kokap sub district, of which 63% were P. vivax and 37% P. falciparum. (13). The 
prevalence of clinical malaria equals 1.5 malaria cases per 100,000 inhabitants 
throughout Java (14). In the malaria focal Purworejo District, malaria incidence 
typically ranges from 2 to 11 cases per 1,000 residents per year and reached 44.5 
per 1,000 in the 2000 epidemic. (13, 15). In Papua, detailed data are scarce. Malaria 
transmission is very focal and generally high compared to the rest of Indonesia, and 
malaria incidence varies depending on geography and ecology (Personal 
communication, Dr M. Bangs). Average prevalences of P. falciparum fluctuate from 
25% to 75% (14, M. Bangs). In the malaria focus and study site Arso Pir, intensity of 
P. falciparum transmission ranges from 0.018 to 0.39 infective bites/person/night 
during the low and high transmission seasons, respectively (75 ibpy). Characteristics 
of distribution of Plasmodium, clinical malaria and Anopheles in the study areas in 
Cameroon and Indonesia are compared in Table 1.1. Prevalence of P. falciparum is 
similar in the Central Province of Cameroon and in Papua. The EIR is also 
comparable in these two areas. Both prevalence of P. falciparum and EIR are lowest 
in Java, compared to the other three areas.  
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Table 1.1: Malaria transmission in field sites in Cameroon and Indonesia 
  Cameroon  Indonesia  
  Yaoundé 
Central 
province Java  Papua 
P. vivax No No Yes Yes 
        
P. falciparum Yes Yes Yes Yes 
        
Prevalence (%) 20-40 30-60 0-1 25-75 
        
Incidence of clinical 50 (16)* 50 (16)* 0.02-11(14)* >100 (17)* 
malaria per 1,000     
        
Most abundant A. gambiae A. gambiae A. aconitus A. punctulatus  
Anopheles vectors A. funestus A. funestus A. sundaicus complex 
        
Entomologic  4-30   30-600 <1 75 
 Inoculation Rate (7, 8, 18)* (7, 9, 19, 20)* Derived from Derived from 
(Infectious bites per   prevalence Arso Pir focus 
person per year)    and (21, 22)* (14)* 
* References 
 
 
1.2  Biology and control of P. falciparum 
 
1.2.1    Biology of P. falciparum 
 
Malaria transmission from one human to another requires an infected and a 
susceptible human, a bloodsucking female anopheline mosquito vector and a time 
lag between mosquito bites on the subjects. Infectivity of parasites to either host or 
vector depends on the life stage of the parasite. The developmental stages of P. 
falciparum and their location in host and vector are schematically shown in Figure 
  General introduction 
 
 14
1.3. Infectious mosquitoes (with sporozoites in the salivary glands) transmit malaria 
via the saliva to the host, when taking a blood meal on a susceptible human . The 
life cycle of the parasite within the host involves three consecutive developments: 
exo-erythrocytic in the liver , asexually  and sexually  in red blood cells. The 
sexual stages start with sexual commitment of asexual parasites. Sexual 
development in the human host is arrested at the mature gametocyte stage , the 
only stage transmittable to mosquitoes. After fertilisation in the mosquito midgut, 
zygote  and ookinete  formation takes place. Ookinetes penetrate the mosquito 
midgut wall. There they develop into oocysts that rupture after maturation, releasing 
thousands of sporozoites  that migrate to the mosquito salivary gland, prior to 
potentially being transmitted via a mosquito bite to humans . 
 
 
Figure 1.3: Biology of P. falciparum. Artwork with courtesy of CDC (Centres for 
Disease Control and Prevention), Atlanta, Georgia, USA. Published with permission. 
(http://www.dpd.cdc.gov/dpdx) 
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1.2.2 Targets for malaria control 
Different life stages of P. falciparum may be affected by interventions, either by 
raising physical barriers for transmission or by the induction of human immunity. 
Transmission from mosquito to man and vice versa may be limited by (insecticide 
impregnated) bed nets or curtains (23, 24). Malaria mortality, morbidity and parasite 
prevalence in children in malaria endemic countries can be reduced dramatically by 
such intervention (25). Some researchers suggest that reduction of transmission 
may lead to a shift of severe malaria to older age groups (26), but this has not been 
confirmed in long-term studies (27, 28). Another intervention is antimalarial drug 
treatment, which may reduce parasitaemias, morbidity and transmission. The Global 
Malaria Eradication programme in the fifties of the twentieth century combined 
insecticide spraying with mass drug administration of chloroquine. Initially, 
transmission was successfully reduced, but soon resistance developed both in 
mosquitoes against insecticides and in parasites against drugs (29). Nowadays, 
artemisinin derivatives are effective alternative drugs for the reduction of asexual and 
sexual parasitaemias, and of infectiousness of gametocytes (30), which was also 
shown in clinical trials with drug combination therapies (31-34). No drug resistance is 
reported as yet in vivo (35), but has recently been shown to occur in vitro against 
field isolates (36, 37). The addition of artemisinin or derived compounds to standard 
treatment has been suggested to limit the spread of drug resistance (38-40). 
Artemisinin (derivatives) should be administered in combination to prevent 
development of drug resistance (41). Combination therapies, Coartem (artemether 
and lumefantrine) and mefloquine + artesunate, are more effective than chloroquine 
plus sulphadoxin/pyrimethamin (42), and prevent gametocyte development (42, 43). 
Vaccination is a third option for malaria control. All parasite stages in the human 
host may be identified as targets for interventions based upon induction of human 
immunity. Vaccine development is slow, though, for scientific and financial reasons. 
One obstacle is the presence of antigenic variation and genetic polymorphism in the 
various stages. Different pre-erythrocytic and asexual blood stage vaccine 
candidates have been tested in clinical trials, most of which proved not effective (44). 
The most advanced pre-erythrocytic vaccine candidate is RTS,S/AS02A based on P. 
f. circumsporozoite surface antigen, which induced reduced prevalence of i) P. f. 
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infection, and ii) of severe malaria, and extended time to infection, in a clinical trial 
with 1-4 years old children in Mozambique (45, 46). However, efficacy and long-term 
effectiveness of any of the single component vaccines currently in clinical trials 
(including RTS,S) do not justify wide scale use, and should rather be combined into 
multi-component vaccines(47). Current progress with RTS,S vaccine studies 
suggests that the development of an effective malaria vaccine is probable (48). 
Furthermore, the publication of the P. f. genome and the progress in genomics and 
proteomics research will help to identify vaccine candidates (49, 50). 
 Transmission blocking vaccines (TBV) consist of sexual stage antigens, which 
show less antigenic variation than antigens from other parasite stages. Therefore, 
TBVs are considered to be promising as a potential tool for malaria control (51). A 
clinical trial in human volunteers vaccinated with recombinant protein Pvs25H 
(derived from P. vivax ookinete Pvs25 surface antigen) showed induction of both 
immunogenicity and TRA (52).  
 
 
1.3 Human host defence against malaria 
 
Malaria morbidity may be counteracted by host defence mechanisms. These 
mechanisms include polymorphisms in human proteins, non-specific innate immunity 
and specific (naturally acquired) immunity. Besides these three personal disease-
limiting host defence mechanisms, transmission-blocking immunity (TBI) exists. TBI 
protects the population against transmission from immune individuals. This very 
immunity is also disease limiting, albeit indirect, and may be referred to as herd 
immunity. 
 
1.3.1  Polymorphisms of human proteins 
 
Polymorphisms of human ligands and receptors may contribute considerably to 
protection against clinical malaria. Especially red blood cell polymorphisms are 
known to increase the chance of survival from malaria infections for people living in 
endemic areas. The “malaria hypothesis” states that malaria parasites affect recent 
human evolution (53), based on the distribution of thalassemia in previous malaria-
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endemic regions around the Mediterranean Sea. Also, heterozygotes of either sickle 
cell trait (defective haemoglobin), glucose-6-phosphate dehydrogenase (G6PD) 
deficiency or band 3 gene (ovalocytosis, abnormal red blood cells) reduce the risk of 
clinical malaria (54, 55).  
The Duffy factor is a receptor ligand for binding of P. vivax on the surface of the 
red blood cell. Black Africans are homozygous negative for the Duffy factor, and P. 
vivax is absent in most of Africa (56-63). 
 
1.3.2  Innate immunity  
 
Following the pathways in the immune response, malaria parasites initially 
generate an innate response followed by specific immune reactions in the course of 
(multiple) infections (64). It has been suggested that innate immunity is induced at 
parasite densities above a certain threshold (65). This is supported by the 
observation of early elevated cytokine responses (sGranzyme A and IFN-γ) in 
experimental P. f. malaria infections in non-immune humans, in association with low 
parasite densities (100par /ml) (66). 
 The host cells involved in innate immune reactions against malaria are dendritic 
cells, macrophages, natural killer (65) cells, NKT cells, and γδ T cells (67). Binding of 
P. f. ligands to innate immune cell receptors may lead to the production of cytokines 
(IL12, IL12p, IL8, IL18, IFN-γ, TNF (66), Mφ activation and subsequent killing of the 
parasites (67). Thus, innate immune reactions may contribute to control parasite 
density. Innate immunity probably acts against all parasite stages (68-70). 
NK cells are suggested to be an early source of IFN-γ, and activate DC and Mφ 
(71). Important cell receptors for activation of innate immunity are Toll-like receptors, 
on DC and Mφ (72). For instance, binding of P. f. degradation product of 
haemoglobin, hemozoin, to TLR9 induces cytokine production and up-regulates co 
stimulatory molecules (73). In addition, TLR2 (74), TLR9 (73), and TLR11 (75) might 
contribute to the initiation of NK cells and Mφ activation (76). Functionality of TLRs is 
illustrated by the observed association of TLR4 polymorphism with morbidity in 
African children (77). Several other target cell receptors have been identified. For 
instance, CD36 on DC bound by P. f. infected erythrocytes induce IL10 secretion 
(78).  
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Innate immunity acts by means of a rapid inflammatory response, which hampers 
parasite development and triggers the adaptive immune system to generate a 
specific humoral and cellular response (67). It has been suggested that cytokine 
production by the innate immune system is controlled by IL-10 and transforming-
growth factor-β, which are both produced by the innate and the adaptive immune 
system (79, 80). 
 
1.3.3   Naturally acquired immunity 
 
Acquisition of protective immunity against clinical malaria in an endemic 
population follows a typical pattern: Infants with high parasitaemias may suffer from 
severe clinical attacks, partially immune children show mild attacks but still may carry 
high parasitaemias and protected adults are usually asymptomatic with low 
parasitaemias (81). An increase in the number of infections in individuals is 
accompanied by a rapidly diminishing probability of malaria attacks and a regressive 
decrease in parasitaemias (82, 83).  
Repeated exposure to P. falciparum leads to the acquisition of specific immunity 
against different parasite stages. The localisation of the parasite stages in the host 
determines the reaction of the immune system. Below a panel of antigens used in 
this thesis is introduced as marker for exposure and protection in endemic 
populations. For pre-erythrocytic stages, circumsporozoite protein (CSP (84)) is the 
antigen of the most advanced vaccine prototype. Vaccination with RTS,S/AS02A 
protects some 37 % of children in Mozambique (46). Antibody responses against P. 
f. asexual stage glutamate-rich protein (GLURP) correlate with protection from 
morbidity and infection in African populations (85, 86). GLURP is expressed on the 
surface of both schizonts and merozoites (87). Antibodies against sexual stage 
antibodies Pfs230 and Pfs48/45 are associated with transmission reduction (88, 89).  
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1.4 Transmission blocking immunity 
 
1.4.1   Mechanism of action 
 
Transmission blocking immunity is caused by a combination of innate cellular 
(90, 91) and naturally acquired humoral immune responses of the human host (88, 
92-95). Human white blood cells reduce the number of gametocytes in the mosquito 
midgut, which depends on serum factors (91). On the other hand, antibodies arrest 
the sporogonic development (96). Transmission from man to mosquito depends 
essentially on the distribution of gametocytes within the human population. The 
highest prevalences and densities of gametocytes are found in the younger age-
groups (1-4 years, 5-8 years) (97-99). The overall negative association of 
gametocytes (density and prevalence) with age suggests that children are a major 
source of transmission. Nevertheless, mosquito feeding experiments on endemic 
populations (see Fig 1.4) in different malaria-endemic countries revealed that the 
high absolute number of infectious adults needs to be considered in the 
determination of the infectious reservoir (100-105). Adults may determine 6-60% of 
the infectious reservoir in various endemic regions (101). 
Mosquito feeding experiments on gametocyte carriers in Burkina Faso indicate 
that the infectiousness of gametocytes is negatively correlated with the age of the 
gametocyte carrier (106). This suggests a role of naturally acquired immunity against 
sexual stage parasites of P. falciparum (107). Similar transmission blocking immunity 
was previously shown for P. vivax in human subjects in endemic areas (108) and in 
various animal models (109-112). These animal studies strongly suggest that sexual 
stage antibodies determine transmission-blocking immunity.  
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Figure 1.4: Feeding of mosquitoes on human blood. A. Direct feeding. Mosquitoes 
(a) feed on the skin of a gametocyte carrier (1), ingest gametocytes (b) and red 
blood cells (2). After 7 days oocysts (c) mature in the mosquito midgut (3). B. Direct 
Membrane Feeding Assay (DMFA). Blood is drawn from a gametocyte carrier (1), 
and suspended in a glass-feeding device, which is covered with a membrane to 
allow mosquitoes (a) feeding on the gametocyte (b) containing content (2). After 7 
days oocysts (c) mature in the mosquito midgut (3). C. Standard Membrane Feeding 
Assay (SMFA). Gametocytes are cultured in the presence of non-immune donor 
blood (1), and manipulated as B. 
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1.4.2   Influence of sexual stage antibodies on transmission  
 
Antibodies against sexual stage-specific surface antigens may affect 
transmission by acting against different stages in sporogonic development. Pfs48/45 
and Pfs230 are expressed on the surface of gametocytes and gametes (female and 
male) (113). The role of gametocyte surface antigen Pfs48/45 in fertilisation was 
demonstrated by gene disruption, which affects male gamete fertility and reduces 
both zygote formation and oocyst production (114). Antibodies against Pfs48/45 may 
block fertilization of the macrogamete (115). Antibodies against Pfs230 can block 
transmission in the presence of complement and act by lysis of gametes (116). 
Antibodies against zygote/ookinete surface antigens Pfs25 and Pfs28 may also block 
transmission, but these antibodies are not induced after natural infection (114, 115).  
Several research groups have studied the effect of specific reduction of 
transmission from man to mosquito with respect to sexual stage antibodies in 
different endemicities. Reduced transmission was shown in populations endemic for 
P. falciparum in Papua New Guinea (117), Sri Lanka (118), Cameroon (119, 120), 
The Gambia (121) and Burkina Faso (106). Antibodies against Pfs48/45 and Pfs230 
were prevalent in gametocyte carriers from all areas. Several transmission blocking 
studies in different endemic areas confirmed the observation of reduced 
transmission in association with Pfs48/45 (88, 93, 121-123) and/or Pfs230 responses 
in human serum (89, 117, 124). However, in other studies no significant association 
was found between reduced transmission and presence of serum antibodies against 
either Pfs48/45 (117), Pfs230 (94, 124) or both (125, 126). The inconsistencies in the 
associations of prevailing sexual stage antibodies and transmission blocking, often at 
comparable endemicities, illustrate the complexity of transmission blocking immunity 
and its measurement. Antibodies against Pfs48/45 and Pfs230 have not been 
longitudinally compared with transmission to date. Such surveys may help to 
understand the dynamics of transmission blocking immunity. 
The variation of sexual stage antigens has been suggested to be limited and far 
less than antigens from other stages. Pfs48/45 showed minimal antigenic variation 
(126), which was confirmed by DNA analysis on P. falciparum clones from different 
origin (125). However, recent studies on field isolates from Africa, Asia and South 
America showed considerable genetic polymorphism in Pfs48/45, although 
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polymorphism of blood stage antigens is much larger (127, 128). The authors 
suggest that Pfs48/45 is under selection pressure. Pfs230 is shown to be more 
variable than Pfs48/45 (125). This implies that sexual parasites may have more 
chance to evade the immune function of Pfs230 than that of Pfs48/45.  
 
1.4.3   Bioassays for the measurement of transmission 
 
Transmission of P. falciparum from man to mosquito can be mimicked by feeding 
of anopheline mosquitoes on the skin of human gametocyte carriers (94, 104, 106, 
129-131) (Table 1.2, Fig. 1.4). This allows for an estimate of the infectiousness of the 
gametocyte carrier, but it may be affected by humoral and vectorial mechanisms. 
The impact of these mechanisms on transmission cannot be determined by skin 
feeding. An alternative assay can be used to estimate the effect of serum on 
transmission, the direct membrane feeding assay (DMFA) (132, 133). In the DMFA, 
blood from gametocyte carriers is fed to mosquitoes through a membrane and 
oocysts are counted after one week. Serum effects are studied by the comparison of 
autologous and non-immune sera as part of the blood suspension offered to 
mosquitoes. The DMFA cannot be used for estimating serum effects of people 
without gametocytes, but the SMFA does (132). In the SMFA, cultured gametocytes 
are membrane-fed to mosquitoes in the presence of human red blood cells and test 
or control serum. Transmission is more efficient in skin feeding experiments than in 
the DMFA, by yielding higher oocyst densities (134) (Table 1.2). However, oocyst 
densities with both techniques were correlated (134). The DMFA is therefore a 
valuable alternative for skin feeding in the analysis of infectiousness of gametocyte 
carriers. Furthermore, Mulder et al. showed previously that prevalences of 
transmission reducing sera in DMFA and SMFA were also correlated (OR 6.1, 95% 
CI 1.6-22.9) (135). 
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Table 1.2: Comparison of mosquito feeding assays 
Mosquito 
feeding 
Assessment Remarks 
Skin Feeding Infection from 
man to mosquito
Most natural condition  
Possible in field setting  
Transmission blocking immunity not assessed  
Gametocyte carrier needed 
Sera cannot be tested 
Blood sampling and feeding in one day 
Mosquito biting on skin ethically unwanted  
DMFA1 
- Serum 
replacement 
Infection from 
man to mosquito
Non-standardised artificial set up 
Possible in field setting 
Transmission blocking immunity not assessed 
Gametocyte carrier needed 
Sera cannot be tested  
Blood sampling and feeding in one day 
Venous blood sampling ethically acceptable 
DMFA 
+ Serum 
replacement 
Effect of serum 
factors or 
antibodies on 
infection from 
man to mosquito
Non-standardised artificial set up 
Possible in field setting 
Transmission blocking immunity can be assessed 
Gametocyte carrier needed 
Limited number of sera can be tested (Max 6/day)
Blood sampling and feeding either on one day or 
on different dates 
Venous blood sampling ethically acceptable 
SMFA Effect of serum 
factors or 
antibodies on 
infection from 
man to mosquito
Standardised artificial set up 
Not possible in field setting  
Transmission blocking immunity can be assessed 
Cultured gametocytes 
More sera can be tested (Max 36/day) 
Time lap in serum collection and feeding 
Venous blood sampling ethically acceptable 
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The effect of serum on transmission can be evaluated by comparing prevalences 
of sporozoites in test and control feeds 14 days after feeding, or by comparing 
densities or prevalences of oocysts one week after feeding. It has been shown that 
the transition from oocysts to sporozoites is highly efficient (135). This allows for the 
use of the oocyst stage as marker for successful transmission, avoiding the 
biological hazard of the infectious sporozoite stage. Calculation methods for the 
effect of serum on transmission are different for DMFA and SMFA. Serum effects in 
DMFA are often non-parametrically determined, comparing prevalences of oocysts in 
test and control samples (94, 96, 133, 136). 
At a minimum, the development of an accurate assay for the quantification of 
transmission blocking immunity is needed for efficacy testing of TBVs. The SMFA is 
especially developed for use as a bioassay for assaying blood from immunised 
individuals independent from the presence of gametocytes in the blood. It is further 
important to validate the calculation method to achieve an optimal comparison of 
immunised and control subjects. 
Different calculation methods for serum effects in SMFA have been evaluated, 
one of which considers the ratio (R) of log transformed oocyst densities in the test 
sample and the difference of the oocyst densities in test and control sample (136). 
This method has its limitations, and can only be used for transmission blocking 
categories. A quantitative measure of the effect of human factors on transmission 
(transmission reducing activity, TRA) may be more accurate and conclusive.  
 
1.4.4   Natural acquisition of TBI 
 
Previous studies by the Medical Parasitology Division on non-immune travellers 
and clinical malaria patients in endemic areas showed that TBI that includes 
antibodies to Pfs48/45 and Pfs230 is more prevalent in gametocyte carriers than in 
non-carriers (137). Among gametocyte carriers, travellers have much higher anti-
Pfs48/45 titres than endemic patients, suggesting that anti-sexual stage antibodies 
are rapidly induced in travellers. In addition, TBI that induces anti-Pfs48/45 
antibodies persists in travellers for almost one year. This is in striking contrast with 
studies in the endemic population where Pfs48/45 or Pfs230 specificities are found in 
less than 10% of the population (138). Furthermore, TBI is more frequently found in 
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endemic individuals with little or no previous exposure to malaria. This may be 
explained by the fact that gametocytes are more prevalent in non-immunes or young 
children in endemic areas and that sexual stage immunity may be readily acquired 
(107). In contrast, gametocytes are rarely found in adults who are immune against 
asexual parasites; therefore boosting of TBI is a relatively rare event and TBI may 
disappear with exposure to malaria parasites over time. Our working hypothesis 
(Figure 1.5) for the dynamics of TBI is that TBI develops rapidly after early exposure 
to gametocytes during early P. falciparum infections and wanes as the number of 
infections increases. Simultaneously, immunity to disease and asexual parasites 
increases.  
 
 
Figure 1.5: Working hypothesis. Acquisition of immunity to sexual and asexual forms 
of P. falciparum (107). 
 
 
1.5 Objectives of the thesis 
 
The general aim of this thesis is to study the impact and pattern of malaria 
transmission on the natural acquisition of transmission blocking immunity. Specific 
objectives are 1) to study the relation between TRA and transmission intensity, and 
2) to improve the SMFA methodology. 
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1.6 Outline of the thesis 
 
This thesis explores P. falciparum transmission blocking immunity in the context 
of transmission intensity. Field studies are conducted in malaria-endemic populations 
in urban and rural Cameroon (meso- and hyperendemic year-round malaria, 
respectively) and a migrant study is conducted in the hyperendemic Papua province 
of Indonesia. Chapter 2 describes an entomological study in the urban field site 
Dakar (Yaoundé, Cameroon). Mosquitoes are captured on human volunteers by 
indoor night catching. The distribution of anopheline species, sporozoite rates and 
the entomologic inoculation rate is determined. In Chapter 3 the impact of seasonal 
fluctuations in transmission intensity on the distribution of asexual and sexual 
parasitaemias in the human population of Dakar is determined. In Chapter 4 
transmission blocking immunity in urban (Dakar) and rural (Koundou) field sites in 
Cameroon, as determined with the DMFA, is compared. In Chapter 5 the 
methodology of SMFA is evaluated, based on hundreds of feeding experiments, and 
the calculation method for TRA is adapted. Associations of TRA with monoclonal 
antibodies, endemic sera and serial dilutions of gametocytes are determined in 
Chapter 6. The existence of transmission enhancement is established in human 
sera  in Chapter 7. The onset of TRA and antibodies against different parasite 
stages is studied in an established cohort of non-immune Javanese migrants in 
hyperendemic Papua (Chapter 8). Here, serum prevalence of TRA and immune 
reactivity are analysed as a function of the number of P. falciparum infections. In the 
discussion in Chapter 9, suggestions are made for further improvement of both the 
SMFA and the calculation of TRA in order to develop optimally accurate methods in 
future studies on transmission blocking immunity. Finally, recommendations are 
formulated for the design of future field and laboratory studies, and alternative 
methods are discussed for the assessment of transmission reduction.  
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Abstract 
 
A longitudinal survey was conducted from January to December 2000 in the 
Dakar quarter of Yaoundé. The aim of this survey was to capture malaria vectors 
and to evaluate malaria transmission. Four anopheline species were captured: 
Anopheles gambiae, A. funestus, A. hancocki and A. nili. A. gambiae and A. 
funestus were found carrying P. falciparum  sporozoites in their salivary glands 
(sporozoite indices were 2.7% and 1.3%, respectively). The parity rates were 53% 
for A. gambiae and 55% for A. funestus, without any significant differences. A. 
gambiae and A. funestus counted for 98% of all anopheline mosquitoes caught 
during the survey, with a mean value of 4 bites per man per night. The entomological 
inoculation rate was 34 infecting bites per man per year. In this quarter, transmission 
was observed throughout the year mostly by A. gambiae (EIR: 30) and secondarily 
by A. funestus (EIR: 4) 
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Introduction 
 
The process of urbanisation and urban industrialisation is usually followed by 
environmental changes, demographic growth and the introduction of sanitary 
systems. In cities in the tropics, urbanisation is generally accompanied by a 
decrease in malaria transmission (139, 140). This situation is explained on the one 
hand by ecological circumstances which limit the development and growth of 
anophelines, and on the other hand by better medical facilities (141). Nevertheless, 
malaria transmission and morbidity remain present in urban areas (142). It has 
previously been shown in Yaoundé, the capital of Cameroon, that malaria 
transmission is weak in one quarter and variable in the other (7, 143). The aim of this 
study is to compare the intensity and seasonality of malaria transmission, and 
describe the Dakar quarter in Yaoundé as an urban field site for the study of malaria 
transmission.  
 
 
Materials and methods 
 
Study site 
 
A mosaic of hills and marshy valleys forms the city of Yaoundé. Yaoundé is 
situated in an equatorial climate zone of the Guinean type with four seasons: two 
rainy seasons (April-June and August-November) and two dry seasons (July and 
December-March). The Dakar quarter, like most of the urban quarters, is built on a 
hill with a faint slope. Four brooklets and a marshy puddle are surrounded by aquatic 
vegetation (Fig. 2.1).  
 
Capture of culicidae 
 
The study of antropophilic anophelines has been done by indoor night capturing 
of mosquitoes by volunteers. Eight houses have been selected in relation to their 
distance to potential mosquito breeding places. These houses were spread 
throughout the quarter, in order to obtain a representative sample of the culicidine 
population feeding on man.  
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Figure 2.1: Plan of the Dakar quarter. Surrounding quarters are Mvolyé, Efoulan and 
Nsam. Houses selected for indoor night capture are numbered 1-8. Marsh, 
connecting brooklets and railroad are depicted in black, the car roads in grey. 
 
In every selected house, two volunteers captured mosquitoes during the night: 
one from 20 hr to 1 hr, the other from 1 to 6 hr. Captures took place one night every 
two weeks, during the course of a year. Permanent rotation of the capturers over the 
houses was applied to diminish possible bias due to human factors. The captured 
anopheles were collected per hr in different bags, and dissected in the laboratory in 
the morning. 
The captured mosquitoes were immediately identified according to morphological 
key criteria (144). A sample of A. gambiae s.l. was determined by PCR (145). The 
parturity rate, i.e. the ratio of parous female mosquitoes and all female mosquitoes, 
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was determined by analysis of the ovarian tracheoles (146). The presence of P. 
falciparum  sporozoites in the salivary glands was determined by optical microscopy, 
after dissection and crushing, without staining. 
 
 
Results 
 
The results cover the period from January to December 2000. Twenty-four night 
captures yielded 4163 female mosquitoes, from four families, in total: Culex (75%), 
Anopheles (18%), Mansonia (7%) and Aedes (0.2%). Four anopheles species were 
captured. The specimen of the gambiae complex tested by PCR all belonged to the 
A. gambiae s.s. species (Table 2.1). 
 
Table 2.1: Composition of the collected culicidae 
Species     N=  %  . 
A. gambiae      577  14 
A. funestus     143   3 
A. hancocki         6   0.1 
A. nili                2   0.05 
Culex sp.             3,132  75 
Mansonia sp.               298   7 
Aedes sp.         2   0.1  . 
 
 
Culicidine density feeding on man  
 
Both A. gambiae and A. funestus were captured every month. The mean daily 
biting rate of A. gambiae was 3 bites per man per night (bpn) with a maximum of 6.4 
bpn in the short rainy season (May-June). The biting rate of A. funestus was 0.7 bpn 
with a maximum of 3 bpn observed in the long dry season (February) (Fig. 2.2). 
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Figure 2.2: The monthly variation of the number of anopheline bites per man per 
night, in Dakar quarter (Yaoundé) 
 
The daily number of bites by Culex sp. was estimated at 16 bpn with a maximum 
of 28 bpn observed during the long dry season (January-February), and that of 
Mansonia sp., at 1.5 bpn with a peak of 3 bpn in June. Inhabitants from Dakar 
receive on average an estimated 8,000 mosquito bites per year. 
 
Parturition rate, sporozoite index and entomological inoculation rate 
 
The annual parity rates of A. gambiae (n=577; 53%) and A. funestus (n=143; 
55%) are comparable. The difference is not statistically significant (X2=0.2; P>0.05). 
The sporozoite indices for A. gambiae and A. funestus are estimated 2.7% and 
1.3%, respectively, and are not significantly different (Yates corrected X2=0.4; 
P>0.05). None of the captured A. hancocki and A. nili mosquitoes carried 
sporozoites in their salivary glands. 
The transmission was evaluated for every vector species by multiplication of the 
daily bite rate and the sporozoite index (s and %). This allows for the calculation of 
the mean entomological inoculation rates per month per species (Fig. 2.3). The sum 
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of the mean EIRs per month yields the annual EIR per species. Inhabitants from the 
Dakar quarter receive on average 34 infectious bites per person per year (ibpy). The 
EIR correlates closely with the total number of anopheline bites per person per year. 
Transmission is principally assured by A. gambiae with 30 ibpy, while A. funestus 
contributes with 4 ibpy, especially during the dry season of February-March when A. 
gambiae density diminishes. 
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Figure 2.3: Monthly entomological inoculation rate, Dakar quarter. 
 
 
Discussion 
 
The results for the Dakar quarter show that the anopheline fauna is not rich in 
species and that mosquito densities are low. Indeed, of the forty anopheles species 
known in Cameroon (147), four are found at the study site: A. gambiae, A. funestus, 
A. hancocki and A. nili. The species A. gambiae and A. funestus are responsible for 
the transmission of malaria in the Dakar quarter. A. gambiae is the major vector and 
A. funestus is an accessory vector. This is the first time that A. funestus is shown in 
Yaoundé (143). The presence of this species and its capacity to transmit malaria 
was associated with particular environmental and ecological factors in the quarter, 
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like the presence of brooklets, a marsh and marchy vegetation, which favour the 
development of mosquito larvae. The potential secondary malaria vectors A. 
hancocki and A. nili, were rarely found (19, 148). 
An increase in the density of A. gambiae was observed after the start of the rainy 
seasons. This increase was partly due to the water in the many pools of water being 
located in in the sun, which is a favourable condition for the development of larvae. 
Our findings agree with previous studies in urban and peri-urban zones, and in 
villages in deforested regions (7, 140, 143), which show that A. gambiae is the major 
urban malaria vector. Similar observations have been reported in degraded and non 
degraded rainy forest zones in southern Cameroon, where it is associated with A. 
moucheti, a forest related vector (149). Therefore, A. gambiae is a very antropophilic 
cosmopolitan vector. The extension of its distribution areas might be favoured by the 
phenomena of deforestation and urbanisation (20). 
In the Dakar quarter, transmission was shown to be permanent and elevated (34 
ibpy). In contrast, studies in other central quarters of Yaoundé, showed that 
transmission was weak and variable from one quarter to the other (7, 143). The 
heterogeneity of urban malaria transmission seems to be consistent, since it has 
also been observed in Brazzaville (140). The distribution and the nature of the 
potential breeding places, as well as the application of anti-mosquito measures in 
order to reduce the contact between man and mosquito (such as impregnated bed 
nets and insecticide spraying), might explain the heterogeneity in results. 
The observed level of transmission and the behaviour of the two vectors involved (A. 
gambiae and A. funestus) suggest that the use of impregnated bed nets will be an 
effective tool for transmission control in the Dakar quarter.  
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Abstract 
 
Data on transmission intensity and prevalences were obtained in an urban district 
of Yaoundé (Cameroon). Transmission level from mosquito to man was determined 
by indoor night capture of mosquitoes on human volunteers, revealing a calculated 
entomological inoculation rate of 34 infectious bites per person per year. Only A. 
gambiae and A. funestus contributed to malaria transmission and their distribution 
was seasonal. 
Bimonthly cross sectional surveys from July 1999 to May 2000 (n=965) showed 
average annual prevalences of 35% P. falciparum  asexual parasites (range 29 to 
38%) and 4,4% gametocytes (range 0 to 6,7%). Prevalence of high parasitaemias 
(>400 parasites/μl) and of gametocytes was seasonal. Prevalence of asexual 
parasitaemias and of gametocytaemias was age-dependent. The potential infectious 
reservoir in this area is dominated by the age group of 0-15 year olds, representing 
75% of carriers of asexual parasites (p<0.001), 85% of carriers of high parasitaemias 
(p<0.001), and 83% of gametocyte carriers (p=0.03).  
Full year logistic models developed from the available data accurately predicted 
parasite prevalences in subsequent analyses, thus permitting a precise 
determination of study samples for intervention and sero-epidemiology studies, and 
analysis of the infectious reservoir in this area. 
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Introduction 
 
Parasitic, human, mosquito and environmental factors determine malaria 
transmission. For malaria control measures that target or include malaria 
transmission such as transmission-blocking vaccines or the use of insecticide treated 
nets (ITNs), it is important to identify and characterise that part of the population that 
primarily contributes to infection of mosquitoes. Two distinct phases in malaria 
transmission can be identified 1) parasite development in mosquitoes after a blood 
meal from an individual with sexual forms (i.e. gametocytes) of P. falciparum, and 2) 
infection of the human host by infectious mosquitoes. 
Most commonly used parameters of malaria transmission include prevalence / 
incidence of gametocytes as parameters for the infection of man to mosquito. 
Determination of infectivity of gametocyte carriers for mosquitoes is more difficult 
and labour intensive and therefore addressed by few studies (101, 104, 105, 150). 
The second phase of the transmission process is defined by the Entomological 
Inoculation Rate (EIR), which reflects the number of infectious mosquito bites per 
year. EIR can be estimated from data obtained by indoor night capture on human 
volunteers (21). 
Beier (21) introduced a simple equation to determine the prevalence of P. 
falciparum based on transmission intensity. This equation describes the parasite 
prevalence on the African continent at large, but it does not allow for an adequate 
estimate of malaria at local level. Factors like season and age have a strong impact 
on the relation between malaria prevalence and intensity.  
In this study the relationship between prevalences of asexual parasites, 
gametocytes and EIR was studied in an urban setting. In addition, transmission 
season and age were analysed to develop logistic regression models that predict 
local prevalences of asexual parasites and of gametocytes. 
Transmission in Yaoundé 
 
 38
Materials and Methods 
 
Study area and subjects 
 
Dakar is a twenty-hectare large urban quarter surrounded by two tarred roads 
and a branch of the Mfoundi River with maximum forty m difference in altitude, at 2 
km south of the administrative centre of Yaoundé (the capital of Cameroon, with1.5 
million inhabitants). The ±1.500 inhabitants live in brick houses. Transmission 
pattern is stable and related to four seasons: the long rainy season from mid August 
to late November, the long dry season from late November to mid March, the short 
rainy season from mid March to mid July and the short dry season from mid July to 
mid August. Repeated cross sectional surveys on prevalence of P. falciparum sexual 
and asexual parasites were performed between July and December 1998, and 
between July 1999 and May 2000. Every two months, human subjects were 
randomly selected with respect to location within the area and age, and asked to 
participate in the current survey. Subjects of all ages (and parents) were informed 
about the purpose of the study and were included after giving consent. Thick blood 
smears from finger prick were made from 109 to 244 subjects per survey, GIEMSA 
stained and microscopically examined. Parasites were counted against 2,000 white 
blood cells (i.e. 1/3 μl). Asexual parasite densities were classified by the number of 
parasites per μl blood: negative (0), Pf + (1-39), Pf 2+ (40-399), Pf 3+ (400-3,999), Pf 
4+ (4,000-40,000) and Pf 5+ (> 40,000). Pf 3+ and higher was considered as high 
parasitaemias. Subjects with parasites and a body temperature above 37.5oC or with 
high parasitaemias were treated with a single dose of Fansidar® (25 mg sulfadoxine, 
1,25 mg pyrimethamine per kg body weight). The National Ethical Clearance 
Committee of Cameroon approved the project.  
 
Entomological inoculation rates (EIR) 
 
Mosquitoes breed in shallow parts of the river branch. Transmission level from 
mosquito to man was determined by indoor night capture of mosquitoes on human 
volunteers from January to December 2000. Eight houses were selected: two close 
to the river and the others spread across the area, at an altitude of maximum 35 m 
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and all at least 100 m apart. Mosquitoes were collected from 8.00 P.M. to 6.00 A.M., 
twice a month. Anopheline species was determined morphologically. Salivary glands 
were dissected and examined for sporozoites under a light microscope. The 
proportion of sporozoite-positive mosquitoes determined the sporozoite index. The 
monthly EIR was determined by the number of sporozoite-positive mosquitoes 
collected per month, corrected to take into account the number of days in that month. 
 
Statistical analyses 
 
Data were analysed using SPSS 9.0 for Windows. Mosquito counts between 
seasons were evaluated with the Mann-Whitney U test. Logistic regression analyses 
were applied for binary outcomes. Log transformed values of both parasite densities 
and age were compared by linear regression. In these analyses non-carriers of 
parasites were excluded. The t test was used to determine differences in parasite 
densities between cross sectional surveys and the χ2 test to compare proportions. 
 
 
Results 
 
Six consecutive cross sectional parasitological analyses (109 to 244 subjects per 
cross section) were performed with bimonthly intervals from July 1999 to May 2000 
in the Dakar district of Yaoundé. In addition, entomological data were collected 
during the period January to December 2000. Thus, the cross sectional study and 
the entomological study overlapped during the period of January to June 2000. 
 
Entomological inoculation rate 
 
Anopheline species collected were A. gambiae, A. funestus, A. hancocki and A. 
nili (Table 3.1). A. gambiae and A. funestus were by far the main vectors that 
contributed to malaria transmission. The corresponding sporozoite infection rates 
were 2.6% for A. gambiae and 2.2% for A. funestus. The calculated entomological 
inoculation rate was 34 infectious bites per person per year (ibpy). A. gambiae was 
the major vector with 28 ibpy and A. funestus the second with 6 ibpy. Neither the 
overall exposure to anophelines (Z=-1.54, p=0.12) nor the number of infectious bites 
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(Z=-0.69, p=0.49) depended on season, but there was a distinct distribution of 
anopheline species in different seasons. A. gambiae was more often present during 
the wet season (Table 3.1) (Z=-1.97, p=0,05), while there was a tendency that A. 
funestus appeared more often during the dry season (Z=-1.81, p=0,07).  
 
Table 3.1: Number of captured and infected anophelines by species, the relation to 
season, proportion of species and sporozoite infection rate 
Anopheles species  
Dry 
season 
Wet 
season
% Of all 
mosquitoes*1
Sporozoite 
infection rate (%)
A. gambiae Total 136 468 79,9 
 Infected 4 11 83,3 15/581=2,6 
A. funestus Total 88 55 18,9 
 Infected 2 1 16,7 3/138=2,2 
A. hancocki Total 6 1 0,9 
 Infected 0 0  
A. nili Total 0 2 0,3 
 Infected 0 0  
All anophelines Total 230 526  18/819=2,2 
 Infected 6 12  
 
*1 Proportion of all mosquitoes per species 
 
 
Prevalence and density of P. falciparum asexual parasitaemias  
 
The median age for the overall study group of Dakar was 11 years (quartiles 5-21 
years, n=965). The average annual prevalence of P. falciparum was 35% (range 29 
to 38%; Fig. 3.1a). The prevalence was not significantly different during the dry and 
wet seasons. The density of asexual parasites of parasite carriers, however, 
changed with the seasons. In September, the geometric mean of the density in 
parasite carriers was higher than in March (β = 1.08, se (β) = 0.21, p<0.001), 
November (β = 0.77, se (β) = 0.20, p<0.001) and May (β = 0.81, se (β) = 0.20, 
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p<0.001). In July, the density was higher than in March (β = 0.83, se (β) = 0.23, 
p<0.001). 
The prevalence of high parasitaemias was significantly higher in the wet season 
(OR=2.02, 95% CI 1.10-3.72, p=0.01) with only 3% of all cases occurring at the end 
of the long dry season, i.e. in March (Fig. 3.1a).  
The prevalence of asexual parasites (OR=0.98, 95% CI 0.97-0.99, p<0.001) and 
of high parasitaemias (OR=0.96, 95% CI 0.94-0.98, p=0.001) decreased significantly 
with age (Fig. 3.1b). Parasite density was negatively associated with age in parasite 
carriers (β=-0.65, se (β)=0.14, p<0.001). 
 
Prevalence and density of P. falciparum gametocytes  
 
The average annual prevalence of P. falciparum gametocytes in Dakar was 4.4% 
(range 0 to 6.7%), (Fig. 3.1a). Gametocyte prevalence was significantly higher in the 
wet seasons (logistic regression, OR=2.54, 95% CI 0.99-6.53, p=0.05). Gametocyte 
density, however, was neither related to the bimonthly cross-sectional analysis nor to 
season. Gametocyte prevalence diminished statistically significantly with age (Fig. 
3.1b; OR=0.96, 95% CI 0.92-0.99, p=0.002). There was a non-significant negative 
association of gametocyte density with age in gametocyte carriers (β=-0.28, se 
(β)=0.14, p=0.06). 
 
Comparison of EIR with prevalence of parasites 
 
Study of the relation between EIR and prevalence of P. falciparum was only 
possible for the period from January to June 2000 (n= 395), when the bimonthly 
cross-sectional analyses overlapped with the entomological studies. The 
prevalences of P. falciparum asexual parasites, of high parasitaemias, and of 
gametocytes were statistically significantly associated with EIR and age in this period 
(Table 3.2a). The negative association of parasite prevalence with age is in 
accordance with the data of the prevalence study conducted over one year.  
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Figure 3. 1: Prevalence of P. falciparum  asexual parasites (  g  ), high asexual 
parasitaemias (   g   ), and gametocytes (  О  ) a) from July 1999 to May 2000, and b) 
for different age groups.  
 
The potential infectious human reservoir  
 
The point prevalences of asexual parasites, high parasitaemias, and 
gametocytes were highest in the age group 0-15 years, containing 75% (95% CI 74-
76%) of carriers of asexual parasites, 85% (84-86%) of carriers of high 
parasitaemias, and 83% (81-85%) of gametocyte carriers. In addition, more carriers 
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of asexual and sexual parasites were found in the wet season. The potential human 
reservoir of subjects under 16 year in the wet season (462/953 = 48%) reached 
levels of 58% (95% CI: 56-60%) of all carriers of asexual parasites, 73% (71-75%) of 
all subjects with high parasitaemias, and 75% (73-77%) of all gametocyte carriers.  
 
Estimation of parasite prevalences  
 
Established risk factors for malaria were studied for possible associations with 
the prevalences of sexual and asexual parasites. Young age and EIR were positively 
associated with higher prevalences of asexual parasites, but not with transmission 
season. Young age, EIR and wet season were positively associated with the 
prevalence of high parasitaemias. Young age, wet season, asexual prevalence, 
prevalence of high parasitaemias and asexual density were each positively 
associated with increased gametocyte prevalence, unlike the EIR. 
The most appropriate logistic models for prevalences of asexual parasites, high 
parasitaemias, and gametocytes are depicted in Table 3.2b, taking into account 
asexual prevalence, asexual density, age, season and gender, respectively. 
With these models, prevalences of asexual parasites and of gametocytes can be 
estimated in relation to age and season. If a determined number of parasite carriers 
need to be included for a certain study, the models accurately estimate how many 
subjects are to be selected. The season determines the sample size. The models 
predict, for example, that 363 per 1,000 subjects from 5 to 15 years old in the wet 
period will carry asexual parasites, 119 will carry asexual high parasitaemias, and 44 
will carry gametocytes These predictions were compared with independently 
measured prevalences of 37,6%, 11,8% and 3,6% respectively, in 4 cross-sectional 
surveys performed in 1998 (n=783). In this example predicted and observed values 
are very similar. Thus, the applied logistic models for the prevalence of the asexual 
and sexual stages are important tools for study design in this area. 
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Table 3.2: Logistic regression models for prevalences of 1) asexual parasitaemias, 
2) high parasitaemias, and 3) gametocytes, a) in relation to EIR (January – May 
2000, n=965), b) in relation to transmission season (July 1999 – May 2000, n=392). 
Prevalence Explanatory Parameter 
estimate 
Odds ratio (95% 
confidence interval) 
P-value 
  a 
Intercept -1.21 <0.001 
EIR (ibpm*1) 0.18 1.20 (1.06-1.36) 0.004 
Asexual 
parasites 
Age (years) -0.19 0.98 (0.97-1.00) 0.02 
Intercept -4.75 <0.001 
EIR 0.44 1.55 (1.05-2.29) 0.03 
High 
parasitaemias 
(Pf 3+ or 
higher) 
Age -0.019 0.98 (0.95-1.02) 0.3 
Intercept -1.72 0.04 
EIR -0.33 0.72 (0.49-1.06) 0.09 
Gametocytes 
Age -0.093 0.91 (0.81-1.03) 0.13 
 b  
Intercept -0.35  <0.001 Asexual 
parasites 
Age (years) -0.022 0.98 (0.97-0.99) <0.001 
Intercept -2.39  <0.001 
Age  -0.038 0.96 (0.94-0.98) <0.001 
High 
parasitaemias 
(Pf 3+ or higher) Season 
(wet/dry) 
0.76 2.15 (1.16-3.96) 0.01 
Intercept -3.60  <0.001 
Carrier of 
asexual 
parasites (y/n) 
0.65 1.92 (1.01-3.66) 0.05 
Age  -0.043 0.96 (0.92-0.99) 0.01 
Gametocytes 
 
Season  0.90 2.46 (0.94-6.39) 0.06 
*
 
1 EIR = monthly entomological inoculation rate. Ibpm= infectious bites per person per month 
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Discussion 
 
The present study demonstrates that the occurrence of malaria in the urban 
Dakar district is dependent on season and age. The observed transmission intensity 
in the Yaoundé quarter of 34 ibpy was comparable to that of four other urban sites in 
Cameroon (EIRs between 4 and 30 ibpy) (7, 18, 151). In contrast, transmission 
intensity in the Yaoundé outskirts Simbok (566 ibpy) and Etoa (511 ibpy) at 3 and 6 
km from our study site was much higher (9). Malaria transmission in Dakar was 
moderate. Therefore, Dakar may be considered representative for urban Cameroon 
in terms of transmission intensity (152). 
The prevalence of P. falciparum asexual parasites was stable and independent 
of the transmission season. Density, however, was seasonal. Peak density 
manifested itself a month after the start of the long rainy season, in September, at 
which time it was significantly higher than in March (end of dry season), May (start of 
wet season) and November (end of wet season). The density was also higher at the 
end of the short rainy season (in July) than in March. These data indicate a waning 
of parasitaemias during the long dry season, but not to the extent that prevalence of 
parasitaemias diminished. Persistence of low-level parasitaemias (under Pf 3+) 
during the dry season suggests that people protected from disease remain carrier of 
the parasite. The combination of non-seasonality of parasite prevalences and 
changes in seasonal densities was also found in studies in Burkina Faso (100) and 
Tanzania (153, 154). Our study did not show an effect of the short dry season (mid-
July to mid-August) on reduction of parasite prevalence and/or density. The 
prevalence of P. falciparum gametocytes in Dakar was higher in the wet season, 
unlike density. For density the number of gametocyte carriers probably was too low 
to detect a significant difference.  
Beier et al. (21) published an equation to estimate the prevalence of maximum 
asexual parasites for any age group, based on local EIRs. This estimate conforms 
with the data for large parts of Africa. But exceptions are described, notably in the 
urban region of Pikine in Senegal. In our (urban) study site we found a comparable 
deviation. The estimate for the maximum asexual prevalence in the Dakar quarter 
using Beiers equation yielded 24,2*LOG (EIR)+24,68=62%, which is considerably 
higher than the experimentally determined prevalence of 40%. Although the low 
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number of captured infected anophelines may influence the accuracy of the 
determined EIR (18), a tenfold lower EIR should have been observed to explain the 
difference between 62% and 40%. Pikine was regarded as an outlier due to good 
access to medical care and drugs, which might reduce prevalence (21). This may 
account for Dakar as well. The influence of drug use is certainly more relevant in 
urban areas as compared to rural areas. Our study shows that for an accurate 
prediction of local prevalences, parasite data need to be collected locally. 
The prevalence of P. falciparum asexual parasites was constant (40%) in 
subjects under 16 years and declined in older subjects. Density of asexual and 
sexual stage parasites and prevalence of high parasitaemias decreased with age. 
Exposure probably results in parasite reduction. 
The infectious human reservoir is defined by the proportion of gametocyte 
carriers that infects mosquitoes (100, 104, 105, 150, 155). In our study, the age 
group under 16 years represented the highest prevalence of carriers of both sexual 
and asexual stage parasites. This age group is the likely source for transmission to 
mosquitoes. These conditions are strongest during the wet season. In other studies, 
older age groups are considered to substantially contribute to the infectious reservoir 
based on the composition of the population. In studies in Burkina Faso, all age 
groups contributed equally to the infectious reservoir, whereas infectivity of 
gametocyte carriers was age-dependent (100, 150). Muirhead-Thomson (105) 
showed that microscopic detection of gametocytes as a parameter of the infectious 
reservoir leads to underestimation of 1) the size of the reservoir and 2) the 
contribution of older age groups to transmission of the parasite. In Yaoundé, the 
study sample contained 63% of subjects less than 16 years of age. In view of the 
age-dependent gametocyte carriage, the proportion of older subjects contributing to 
infection is probably of less importance.  
The prevalence of the parasite stage involved in transmission from man to 
mosquito, the gametocyte, positively correlates with initial asexual parasitaemias and 
season and negatively with age. For a better comprehension of transmission, the 
gametocyte development in carriers of asexual parasites, and the infectivity of 
gametocyte carriers to mosquitoes should be determined over time. The difference in 
age-dependent prevalence of gametocytes and asexual parasites suggests 
independent rather than simultaneous development of immunity against asexual and 
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sexual stage parasites. This may be elucidated by the determination of the dynamics 
of immunity against the different parasite stages.  
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Abstract 
 
TRA was studied in relation to age, gametocyte density and transmission 
intensity. Subjects with high gametocytaemias were selected in a hypo-endemic 
urban district and a hyper-endemic rural area in South Cameroon. TRA was 
determined in blood from gametocyte carriers in a bioassay, with either autologous 
plasma (OWN) or control serum (AB). Mosquito infection rates (IR) were compared. 
Infection rates correlated positively with gametocyte and oocyst densities. Three 
TRA parameters were analysed: the prevalence of transmission reducers (IRAB < 
IROWN, p<0.01), the mean level of TRA (IRAB - IROWN), and the proportion of non-
infected mosquitoes due to TRA [(IRAB - IROWN)/(100-IROWN)]. A univariate analysis 
could not discriminate between areas with regard to either the prevalence of 
transmission reducers (urban 15% and rural 29%) or the mean levels of TRA (urban 
and rural 9%), or the proportion of non-infected mosquitoes due to TRA (urban 10% 
and rural 13%). There was no relationship between the three parameters and age, 
but a trend of increasing values was observed with rising gametocytaemia, which 
was considered as predicting factor. A multivariate analysis showed that the 
probability of being a reducer was 5.2 to 5.8 fold higher with gametocytaemias above 
150/μ l and 4.6 fold higher in the rural area than in the urban district. 
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Introduction 
 
Malaria infection stimulates the progressive development of immunity in endemic 
areas. Focusing on immunity against sexual stage parasites, gametocytes might be 
affected by different mechanisms: natural selection of asexual parasites (156), 
specific suppression of gametocytes independent from the immune control of the 
asexual parasitaemias (156, 157), reduction both asexual parasites and 
gametocytes by immunity against PfEMP1 (158), and TRA (TRA). The latter is only 
effective in the mosquito midgut on the free sexual stages after ingestion of a blood 
meal from an immune individual (159). The free parasite stages, exposing the same 
antigens as in the human host (e.g. Pfs45/48 and Pfs230), are recognized by the 
different immune components of the blood and can be destroyed. In this respect, 
natural TRA might regulate malaria transmission (160).  
 TRA is usually estimated by establishing infectiousness of gametocytes to 
mosquitoes, comparing endemic immune sera (batch OWN) with non-immune 
control serum of AB blood group (batch AB). Two tests are available. The SMFA is 
performed using cultured gametocytes of P. falciparum (161); while in the DMFA 
blood of gametocyte carriers is used as a source of infectious gametocytes (120). 
SMFA is considered gold standard, but it is expensive and labour intensive. On the 
other hand, DMFA can be carried out in the field on larger numbers of samples, but 
only blood of gametocyte carriers can be tested.  
Only few studies were performed in the field (117, 118, 120, 121, 162), but a 
large variety of applied methods and parameters was used. Data suggest that 
transmission reduction is probably different from one area to another. The objective 
of this study was to evaluate TRA in relation to age, gametocyte density and 
transmission intensity. Three parameters were determined (i.e. the proportion of 
transmission reducers, the mean level of TRA and the proportion of non-infected 
mosquitoes due to TRA) in rural and urban areas of the equatorial forest in southern 
Cameroon with different transmission intensity. 
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Material and methods 
 
Study area 
 
This study was performed in a rural region, in a degraded equatorial forest area 
of southern Cameroon, previously described by Bonnet et al. (163), and an urban 
district of Yaoundé. A. gambiae (s.l.) and A. funestus, are the main vectors in both 
areas (149, 151). There are two distinct rainy seasons, light rain in April and May 
and heavy rain from July to October. The annual rainfall is on average 1700 mm. 
Malaria transmission is permanent in both areas. The level of transmission was 
estimated by the Entomological Inoculation Rate (EIR) in two different studies in two 
different areas. EIR ranged from 18 to 176 infectious bites per man per year (ibpm) 
in the Mengang region in 1998 (149) and from 3 to 13 ibpm in Yaoundé (151) in 
1992. Malaria is hyper-endemic in the Mengang (forest) region and hypo-endemic in 
Yaoundé (urban area). Morbidity and asexual or sexual parasitaemias are higher in 
Yaoundé than in the Mengang region. Chloroquine was the first-line treatment for 
malaria attacks in the two areas. 
  
Inclusion of gametocyte carriers 
 
Gametocyte carriers were detected by cross-sectional surveys, during the low 
and high transmission periods from 1995 to 1999. Inclusion criteria of gametocyte 
carriers were: aged over four years, with over 20 P. falciparum gametocytes/μl of 
blood. These high gametocyte densities were included in order to obtain substantial 
mosquito infection rates (IRs) after artificial feeding. Symptomatic or non-
symptomatic individuals having an asexual density exceeding 1,000 parasites/μl 
were treated with a single dose of sulfadoxine-pyrimethamine. An impregnated bed 
net was given to the participating individuals as compensation. Parents of the 
children or adult individuals gave informed consent before inclusion in this study. The 
National Ethical Committee of Cameroon approved this study. 
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DMFA 
 
The DMFA technique was previously described by Mulder et al. (1994) (120). 
Briefly, six ml of blood was drawn from the gametocyte carriers into a heparinized 
Vacutainer ® tube. All manipulations were carried out at 37°C in order to reduce 
gametocyte activation.  
• A control batch (Immediate, IM) of 2 ml blood was immediately fed, without 
further preparation, to three-day-old female mosquitoes, through a warm water-
jacketed membrane feeder, for 15 min.  
• Two batches of 2 ml blood were centrifuged 5 min at 700 g. In batch OWN, the 
cell pellet was resuspended in autologous plasma. In batch AB, the plasma was 
removed, replaced by 1 ml of non-immune AB serum, and resuspended. The two 
manipulated blood samples were separately fed.  
• Non-fed and partially fed mosquitoes were removed. The others were kept at the 
insectary on a 10% sucrose diet. Seven days later, the midguts of the surviving 
mosquitoes were dissected and stained with 3 % Mercurochrome in PBS, to 
facilitate the examination of mature oocysts by light microscope (40x lens).  
 
Determination of TRA 
 
Experiments were analysed when three criteria were met. 
1) At least one oocyst per positive midgut observed in the AB batch, as a control for 
gametocyte infectiousness after blood preparation. 
2) A minimum of 20 mosquitoes dissected in each batch, in order to obtain a good 
sensitivity of the comparison between OWN and AB infection rates (IRs). 
3) Comparability of IRs in the OWN and IM batches. Experiments with a significant 
difference in IRs (p< 0.01) were discarded because of suspicion of gametocyte 
activation in the OWN batch. 
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Three parameters of natural TRA were defined:  
• The prevalence of reducers. Plasma from a gametocyte carrier was defined as 
reducing if IROWN was significantly lower than IRAB (p < 0.01). Only large 
differences between OWN and AB batches were expected to be reproducible. 
The oocyst density in the infected mosquitoes was not taken into account 
because it was generally low in DMFA conditions and IR was considered to be 
better comparable (164); 
• The level of TRA, or the difference (IRAB - IROWN); 
• The contribution of TRA to total inhibition (TRA/TI).  
The proportion of non-infected mosquitoes after feeding with autologous plasma 
(OWN) is a consequence of human, mosquito and parasite inhibiting factors (136, 
165), and considered as total inhibition (TI = 100 – IROWN). In the same way, 
reduction of infectiousness with the control serum (AB) is a consequence of only 
mosquito and parasite factors, and considered as Transmission Blocking Activity 
(TBA = 100 - IRAB). Thus, TRA is defined by (TBA – TI), and is equal to (IRAB – 
IROWN). Finally, the relative contribution of TRA to TI is defined by the ratio (IRAB – 
IROWN) / (100 – IROWN).  
 
Statistical analysis 
 
SPSS 10.0 software was used for all statistical analyses. The χ2 test was applied 
to compare prevalences. The Mann-Whitney (MW) and Kruskall-Wallis (KW) tests 
were applied to compare continuous variables, which were not normally distributed 
(age, gametocyte density, IRs, TRA and TRA/TI). Correlations between non-
Gaussian variables were determined by Spearman’s correlation coefficient. Logistic 
regression models were applied on the prevalence of reducers with independent 
variables being area, age and gametocyte density. Variables were ordered: rural and 
urban areas; gametocyte density in categories of 20-50, 51-150, 151-500 and > 500 
gametocytes/μl; age groups of 5-10, 11-20, 21-30, and >30 years. 
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Results 
 
Infectiousness of gametocyte carriers 
 
One hundred and six experiments were included, 75 from the urban district and 
31 from the rural area. Urban gametocyte carriers were older and had higher 
gametocyte densities as compared to rural subjects (Table 4.1). In contrast, oocyst 
densities per positive mosquito and IRs were lower in the urban area. This reduction 
of mosquito infection could be affected by residential area, but also gametocyte 
density and age.  
 
Table 4.1: Age, gametocyte density, infection rate (IR) and oocyst density, after 
feeding with the blood of gametocyte carriers in two areas with different levels of 
malaria transmission. 
Parameters Rural area Urban area Comparisons
 N = 31 N = 75 (*) 
Median age (IQR) 9 (5) 22 (11) P<0.001 
Median gametocyte density (IQR) 80 (126) 208 (438) P = 0.003 
Proportion of infectious individualsIM 87%  92%  P = 0.5 
Median IRIM (IQR) 0.33 (0.48) 0.18 (0.20) P = 0.04 
Median oocyst densityIM (IQR) 4.2 (11.6) 2.3 (3.0) P = 0.02 
N= sample size 
IQR = interquartile range 
Comparisons (*): χ2 test for proportions and Mann & Withney test for medians 
 
There was a weak positive correlation observed between gametocyte density 
and IRIM (r = 0.21, p = 0.04). In addition, oocyst density showed a strong correlation 
with IRIM (r = 0.95, p < 0.001) (Figure 4.I).  
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Figure 4.1: Relationships between infection rate after immediate feeding (IRIM) 
and the corresponding oocyst (A) or gametocyte density (B). A regression line is 
presented for oocyst density in association with infection rate (% infected 
mosquitoes). 
% of infected mosquitoes
G
am
et
oc
yt
e 
de
ns
ity
 (L
og
)
0 20 40 60 80 100
1
2
3
4
B 
 
Transmission blocking immunity 
 
 56
Impact of area, age and gametocyte density on TRA 
 
Reduction of infection was observed in 11 and 9 of the gametocyte carriers, in 
the urban and rural areas respectively. There was a tendency that infection was 
more often reduced by serum of urban (15 %) compared to rural gametocyte carriers 
(29.0 %, χ2 =3.0, p = 0.09, table 4.2). The level of TRA was 9.5% in the urban and 
8.6% in the rural samples (MW = 1081, p = 0.6). TRA/TI was 9.5% in the urban and 
12.7% in the rural samples (MW = 1106, p = 0.8) (table 2). The similarity of the levels 
of TRA and TRA/TI in the two areas indicate that these parameters may lack 
sensitivity. In conclusion, the type of area involved was not solely predictive for TRA. 
 
Table 4.2: The prevalence of transmission reducers, the level of TRA, and the 
contribution of TRA to total inhibition in two areas with different levels of malaria 
transmission 
Rural area Urban area Indicators of TRA 
N = 31 N = 75 
Comparisons 
Proportion of 
transmission reducers  
29 %  15%  P = 0.09 
Median TRA (IQR) 0.09 (0.38) 0.09 (0.18) P = 0.6 
Median TRA/TI (IQR) 0.13 (0.61) 0.10 (0.22) P = 0.8 
Legend: see Table 4.1 
 
No significant difference was observed between the distribution of classes of 
gametocyte density in the batches of reducers and non-reducers (χ2 = 5.0, p = 0.2) 
but there was a positive correlation between gametocyte density and the level of 
TRA (r = 0.22, p = 0.03) or between gametocyte density and TRA/TI (r = 0.24, p = 
0.01). Thus, gametocyte density was a predictive variable for TRA. 
Neither the prevalence of reducers (χ2 = 5.7, p = 0.1), nor the level of TRA (r = 
0.05, p = 0.6), nor TRA/TI (r = 0.046, p = 0.6) was significantly different between age 
groups. Thus, age was not predictive for any of the TRA parameters. 
Parameters that might influence the prevalence of transmission reducers 
(residential area, age and gametocyte density) were analysed in logistic regression 
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models. Age was not predictive, neither as a continuous, nor as a categorical 
variable. In Table 3 the odds ratios for transmission reduction in relation to to type of 
area and gametocyte density categories are shown. The probability that an included 
gametocyte carrier was a transmission reducer was significantly higher (4.6 times) in 
the rural area than in the urban district. Furthermore, this probability was significantly 
higher (5.2 –5.8 times) in subjects with high (>150/μl) as compared to low 
gametocyte densities (<150/μl).  
 
Table 4.3: Logistic regression model for the prevalence of transmission reducers in 
relation to area and gametocyte densities.  
Explanatory 
Variable (1) 
Parameter 
estimate 
Odds ratio 
(95% confidence 
interval) 
P-value 
Intercept - 2.9  < 0.001 
Area  1.5 4.6 (1.4 – 15.6) 0.01 
Gametocyte/μl blood    0.06 
51-150 - 0.04 1.0 (0.2 – 5.5) 0.96 
151-500 1.7 5.2 (1.0 – 27.7)   0.05 
> 500 1.8 5.8 (1.1 – 30.7) 0.04 
(1) Coding of the parameters: Area (urban = 0, rural = 1); Gametocytaemia (20-50 / 
μl = 0) 
 
 
Discussion 
 
TRA was estimated by DMFA. A sample of gametocyte carriers with high 
densities of sexual parasites was selected in a hypo-endemic urban district and a 
hyper-endemic rural area in southern Cameroon.  
Infection rates (IRIM) and oocyst densities after immediate infections were lower 
than anticipated, especially with urban blood samples. In addition, 12 out of 106 
gametocyte carriers were not infectious to mosquitoes after immediate infections, in 
spite of high densities of sexual stages. This could be explained partly by a reduced 
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efficiency of the IM feeding method as compared to direct feeding on the skin (i.e. 
the gold standard) (133). However, the prevalence of infectious gametocyte carriers 
rate was higher in our study than previously shown by Mulder (120). The 
combination of high gametocytaemia with relatively low infectiousness suggests that 
inhibiting mechanisms act on parasite development in the mosquito. 
The possibility that reduction of infectiousness associates with serum factors was 
studied by comparing autologous plasma and control serum in the DMFA. 
Transmission reduction was shown in 15% of the urban and 29% of the rural 
gametocyte carriers. The existence of transmission reducing plasma was previously 
observed in other endemic areas (117, 118, 120, 161, 166). A comparison with those 
studies is difficult, because of differences in applied methods, inclusion criteria and 
definition of transmission reduction. However, the prevalence of transmission 
reducers in southern Cameroon and the contribution of TRA to total inhibition seem 
to be low with regard to the mean gametocyte density in the selected individuals. 
This observation might be explained by two complementary hypotheses. Firstly, 
TRA, which is analysed with present gametocytes, might be a consequence of a 
previous wave of gametocytaemia. Secondly, P. falciparum sexual immunity might 
be short-lived, like in P. vivax infection (108, 166), and inhibition might have returned 
at a low level at the time of the DMFA. To support this last assumption, it is 
interesting to note the absence of any relationship between TRA and age. There 
would have been no accumulation of sexual immunity. In addition, our results 
strongly suggest that TRA depends on recent exposure of gametocytes and on the 
number of gametocyte exposures. 
The prevalence of transmission reducers in gametocyte carriers was higher in 
the rural area (29%) as compared to the urban area (15%). Bonnet et al. (167) 
previously observed a comparable prevalence of transmission reducers in 
gametocyte carriers in the same rural area of southern Cameroon (40-44%). That 
study furthermore showed that natural TRA can be estimated either directly on a 
representative sample of individuals, independently of their parasitological status; or 
indirectly on a sample of gametocyte carriers. In this case, the true prevalence of 
reducers in the total population can be estimated by the product of the observed 
proportion of reducers and the gametocyte index in the total population. This type of 
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direct or indirect estimation was previously proposed by Graves et al. (131) to 
determine the probability of an infectious blood meal to mosquitoes.  
Premawansa et al. (118) hypothesized previously that the level of natural P. vivax 
TRA is higher in hyper-endemic malarial areas than in epidemic areas. In our study, 
the prevalence of P. falciparum transmission reducers is elevated in carriers of high 
gametocytaemias and in the rural area. In addition, the level of TRA was not 
significantly different in relation to gametocytaemia and area. Gametocytaemia is a 
better predictor for TRA prevalence than type of area. Furthermore, age and 
gametocytaemia were higher in the included urban subjects in our study. Previously 
was shown that gametocytaemias are elevated 1) in areas with low transmission 
intensity, and 2) in children, especially in infants (149, 163). One may expect that 
prevalence and level of TRA in the whole population be elevated in areas with low 
transmission. Possibly the difference in transmission intensity is too limited in our 
study to show this. Comparison of large differences in transmission intensity might 
be more conclusive to determine the role of transmission intensity and age on TRA. 
In conclusion, it is possible to estimate the level of natural TRA in the field based 
upon at least one sensitive parameter (the proportion of reducers) and a 
standardized methodology. The impact of TRA on malaria transmission and on 
malaria epidemiology still needs to be elucidated: a new and interesting challenge!  
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Abstract 
 
Host responses to the transmittable stages of the malaria parasite may 
effectively reduce transmission. TRA of human serum can be determined as a 
percentage, using the SMFA. This laboratory assay was evaluated using the results 
of 121 experiments with malaria-endemic sera among which many repeated 
measurements were obtained. The assay consists of the feeding of A. stephensi 
mosquitoes with cultured P. falciparum  gametocytes, mixed with human red blood 
cells, and control and experimental sera. The TRA of individual sera was determined 
by the comparison of oocyst densities between these sera. Bootstrap data on oocyst 
densities in individual mosquitoes in control feeds were used to construct confidence 
limits for TRA percentages of serum feeds. Low (<20%) and high TRA (>90%) 
values for individual sera were usually reproduced in a second experiment, whereas 
this was more difficult for values between 20% and 90%. The observed variability of 
TRA values is explained in part by the variability in oocyst density per mosquito. 
Oocyst densities in control feeds varied more between experiments than within 
experiments and showed a slight decline over the three years of experiments. 
Reproducibility of TRA of field sera was low (20%) between experiments, but much 
higher (61%) within experiments. A minimum of 35 oocysts per mosquito in control 
feeds gave optimal reproducibility (44%) between experiments. We recommend that 
1) sera are compared within an experiment, or 2) assays are only analysed where 
controls contain at least 35 oocysts per mosquito. Under the recommended 
conditions is the SMFA appropriate for the study of factors that may influence TRA, 
e.g. transmission blocking vaccines. 
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Introduction 
 
Malaria transmission from person to person is accomplished through infected 
anopheline mosquitoes as vectors. Infectivity of parasites to either host or vector 
depends on the life stage of the parasite. Infectious mosquitoes (with sporozoites in 
the salivary glands) transmit malaria via saliva to the host when taking a blood meal 
on a susceptible human. The life cycle of the parasite within the host involves three 
consecutive developmental phases: pre-erythrocytic in the liver, and asexually and 
sexually in red blood cells. The sexual phase starts with sexual commitment of 
asexual parasites. Sexual development in the human host is arrested at the mature 
gametocyte stage, the only stage transmittable to mosquitoes. After fertilisation in 
the mosquito midgut zygote and ookinete formation takes place. Ookinetes penetrate 
the mosquito midgut wall. There they develop into oocysts that rupture after 
maturation releasing thousands of sporozoites that migrate to the mosquito salivary 
gland, before potentially being transmitted via a mosquito bite to humans. 
Human factors such as specific antibodies (88, 93, 124, 168), neutrophils (90, 
91) and cytokines (91, 169) may interfere with sexual development of parasites in 
mosquitoes and thus may inhibit transmission from man to mosquito. Transmission 
blocking factors have therefore become part malaria control startegies. The recent 
attempts to develop a transmission blocking vaccine (TBV) (170, 171) highlights the 
need for a transmission assay for the evaluation of such vaccines.  
The SMFA has been developed for the determination of TRA of individual sera 
(161). In the SMFA, in vitro cultured gametocytes are mixed with red blood cells and 
human serum, and fed through membrane feeders to laboratory reared anopheline 
mosquitoes (172). TRA is based on the ratio of the number of oocysts developed in 
mosquito midguts comparing test and control sera (136). In order to reduce 
variability between experiments Lensen standardised the method with a limited 
number of sera from Dutch non-exposed donors and from endemic gametocyte 
carriers.  
The objective of this study is to optimize the measurement of TRA by 
retrospective analysis of a large set of data with control and field sera, including 
many repeated measurements with the same sera.  
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Materials and methods 
 
Sera 
 
Non-immune control sera were obtained from Nijmegen blood bank donors. Only 
sera that were tested negative in the SMFA were added to a large serum pool that 
served as a long-term negative control for feeding experiments. The sera from 
Cameroon (n=117) and Tanzania (n=190) were collected in studies on malaria 
transmission and transmission blocking immunity (173, 174). Subjects of all ages 
(and parents) were informed about the purpose of the study, in cross-sectional 
surveys. Thick blood smears were made from finger pricks, Giemsa stained and 
microscopically examined. Subjects with parasites and a body temperature above 
37.5oC or high parasitaemias (>400/μl blood) were treated with chloroquine 
(25mg/kg over 3 days, Tanzania) or a single dose of Fansidar® (25 mg sulfadoxine, 
1.25 mg pyrimethamine per kg body weight). Gametocyte carriers as from 5 years of 
age were included after consent was obtained from their parents or guardians. 
Venous blood (5 ml in BD Vacutainer® serum tubes) was taken sterile and serum 
collected after centrifuging (5 min 2,000 rounds per min). The National Ethical 
Clearance Committee of Cameroon, the Tanzania Commission for Science and 
Technology (COSTECH), and the Ifakara Health Research and Development Centre 
approved the projects.  
 
Transmission blocking bioassay 
 
A bioassay to determine transmission reducing capacity of sera was originally 
described by Ponnudurai et al. (161, 172) and standardised by Lensen et al. (136). 
All serum samples were inactivated by heating at 56oC for 30 min. P. falciparum  
NF54 gametocytes were produced in an automated tipper system in red blood cells 
(rbc) of blood group O and non immune AB serum (175) and harvested after 13 and 
14 days. Quality of gametocytes was estimated by Giemsa stained thin smears and 
exflagellation assays. Infectivity of gametocytes was determined by a prefeed. 
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Prefeed 
 
Fresh heparinized donor blood (10 mL, blood group O) was centrifuged (10 min, 
500 g), buffy coat and plasma were removed, then the rbc’s were washed with 
phosphate buffered saline (PBS, pH 7.4) and the packed cells (pc) stored at 4oC until 
used. 150 μl prewarmed (37oC) pc and 250 μl gametocyte suspension (13 day 
culture, gametocytaemia of 0.5-1%, 2% haematocrit (hc) were added to Eppendorf 
centrifuge tubes and centrifuged (20 s, 13,000 rounds per min). The supernatants 
were removed, the pellets resuspended with 150 μl warm normal human serum, 
vortexed for 2 s and fed in 300 μl aliquots (53% hc) to 50 laboratory reared A. 
stephensi mosquitoes (3-5 days old) for 10 min in prewarmed (37oC) glass feeding 
devices, through Parafilm® membrane. Non-fed and partially fed mosquitoes were 
removed. Remaining mosquitoes were kept at 26oC and >80% humidity. Sucrose 
(5%) was offered ad libitum. Twenty hr after the feed, midguts of five mosquitoes 
were dissected and the midgut contents were stained with 50 μl FITC-labelled 
mouse MoAb anti-Pfs25 in 0.05% Evans Blue. Ookinetes were examined by 
fluorescence microscopy. If mosquitoes harboured more than 100 ookinetes per 
mosquito, this gametocyte preparation was then immediately used for experimental 
feeds as it was considered likely to achieve a 90% infection rate in control 
mosquitoes. 
 
Experimental feed 
 
A feeding experiment consisted of batches of mosquitoes simultaneously feeding 
on up to twenty membrane feeders. Most of the time, triplicate control feeds were 
included with non-immune control serum and seventeen different endemic serum 
test samples. Serum was diluted in non-immune control serum (0.64 v/v) and 
suspension dilution was 0.30 v/v. After a week, approximately twenty mosquitoes per 
batch were dissected, midguts were stained with 2% Mercurochrome in PBS for one 
min. and oocysts were counted per midgut using a microscope. Conditions for 
inclusion of experiments were 1) at least two controls and 2) at least seventeen 
mosquitoes dissected per control.  
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One hundred and twenty one membrane feeding experiments with endemic sera 
were performed from 1999 until 2001. Experiments were repeated to obtain control 
infection rates of at least 90%, and to confirm the outcome. Experimental feeding of 
248 individual field sera was repeated twice in general, yielding 394 comparisons of 
transmission reduction data.  
 
Data analysis 
 
The SPSS 10.0 software package was used for statistical analyses. Oocyst 
densities and infection rates were compared by Spearman’s correlation. The Mann-
Whitney U test was applied for comparisons of test with control feeds, including: 1) 
oocyst densities, 2) coefficient of variation (CV) and 3) infection rates. 
Transmission reducing capacity of serum was determined as reduction in oocyst 
numbers in test samples as compared to a minimum of two control samples: 
 TRA=(TC-T)/TC x 100% (176), where TC represents the arithmetic mean of the 
oocyst density per gut in all pooled control mosquitoes of two to three (or sometimes 
more) feeds within one experiment. Usually twenty mosquitoes were tested, but in 
7% of the controls there were only seventeen to nineteen mosquitoes available for 
analysis. T is the arithmetic mean of the oocyst density of all mosquitoes in a test 
feed within the same experiment. Usually, test feeds were based on 20 mosquitoes, 
but lower values of seventeen to nineteen (7% of feeds) were also considered 
acceptable.  
Bootstrapping was performed using oocyst densities in control mosquitoes of the 
full dataset to study the variability of the observed TRA values (see Appendix 5.1). 
Therefore, data from individual mosquitoes were pooled into groups of mosquitoes 
with increasing average oocysts counts. A number of random samplings and 
redistributions were done; generating 1.2 million simulated data sets. Finally, median 
TRA values and 90% confidence intervals were determined.  
The sign test was applied for the evaluation of 1) possible bias in subsequent 
examinations of the same sera, and of 2) clustering of high (≥ 90%) and low (≤ 20%) 
TRA values of sera in repeated experiments. The number of sera with consistently 
low (or high) observed TRA values in repeated experiments were compared with the 
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expected number(s), based on the fraction of low (or high) observed TRA values in 
the full data set of individual experiments. Pearson’s correlation was applied on 
oocyst densities in replicate controls. Linear regression was applied on oocyst 
densities in controls, with time as independent variable.  
The CV of oocyst densities within and between experiments was compared, 
using arithmetic means of oocyst densities per experimental feed. For the 
determination of the CV between experiments, the individual feeds were randomly 
rearranged in a new data set, with an equivalent distribution of feeds in experiments. 
The average CV values within (observed) and between (random) experiments were 
compared by the Mann-Whitney U test. 
The proportion of repeated feeds that had overlapping 90% confidence limits of 
bootstrap derived TRA values was determined for individual sera. The random 
overlapping proportion was estimated by comparing confidence intervals for sera, 
measured once and in independent experiments, in all possible combinations. 
Reproducibility of TRA was defined as 100% times (overlap in feed repeats – 
random overlap)/(1-random overlap).  
 
 
Results 
 
Variability in oocyst density 
 
For an overview of the oocyst distributions in feeding experiments, experiments 
with at least two controls were selected. The 466 control feeds of the selected 201 
feeding experiments were sorted and clustered by increasing average number of 
oocysts per feed (Fig. 5.1). Oocyst numbers were highly variable at low densities. 
CV of feed cluster 1 (average of 2.7 oocysts per mosquito) was 1.94 (95% CI: 0.82-
4.47). Variation decreased gradually with rising oocyst densities. CV of feed cluster 5 
(117.1 oocysts per mosquito) was 0.56 (95% CI: 0.37-0.83). Furthermore, the 
prevalence of non-infected mosquitoes decreased to below 10%, at increasing 
oocyst densities (>15 oocysts arithmetic mean (AM) per mosquito). Thus, an 
increase in the average oocyst density reduced its variation. 
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There was a modest positive correlation between oocyst density and prevalence 
of infection (n=1299, r=0.577, p<0.001). Oocyst densities were significantly lower 
with test sera (AM 33.2 oocysts per mosquito, n=957) as compared to control sera 
(AM 44.9 oocysts, n=342) (p<0.001). The variation, however, between test and 
control feeds (CVtest=1.11, CVcontrol=1.07, p=0.11) was not significantly different. 
Furthermore, prevalence was not significantly different between test sera (78.5%) 
and control sera (81.4%) (P=0.09). Thus, oocyst distributions with test and control 
sera were similar in experimental feeds. 
Variation was also studied within experiments. Oocyst distributions from 261 
replicate controls within 138 experiments were compared (Fig. 5.2). Every data point 
represents a pair of control feeds within an experiment. Correlation between pairs of 
controls within experiments was strong (r=0.850, p<0.001), but was negatively 
influenced by some outliers. The data points in the figure have an ellipsoid shape 
along the diagonal axis, indicating that variability between experiments was larger 
than within experiments. This is confirmed statistically, by the comparison of CV 
values. The observed variability in oocyst densities within experiments (CV = 0.38; 
95% CI 0.04, 1.07) was 2.2 times smaller than the simulated variability between 
experiments (CV = 0.83; 95% CI 0.21, 1.48) (p<0.001). Furthermore, oocyst 
densities in control feeds appeared to diminish slightly with time (Fig. 5.3, B=-8.27, 
se (B)=3.19, p=0.01; 95% CI: -14.53, -2.00). 
Thus, differences between experiments resulted in a considerable variability in 
oocyst densities and the level of average oocyst densities reduced slightly with time. 
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Figure 5.1: Oocyst distribution per mosquito in clusters of control feeds (1-5) based 
on average oocyst densities per mosquito midgut (2.7, 15.0, 31.6, 59.2 and 117.1 
respectively). Prevalence of infection was 48.6, 81.5, 91.3, 94.2 and 97.8% 
respectively.  
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Figure 5.2: Variability of oocyst density between control feeds within experiments. 
Arithmetic means of oocyst densities per feed are depicted and 1 was added for all 
values to present all data points (including mosquitoes without oocysts) on log scale. 
Every data point represents a feed pair within an experiment. All feed pairs resulted 
from replicate controls within independent experiments with at least 17 mosquitoes. 
Most experiments contained three control sera, resulting in three comparisons. 
There are 261 comparisons in the figure. The addition of 1 was not used in statistical 
analysis. 
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Figure 5.3: Oocyst density in control mosquitoes during the experimentation period 
1999-2001 declines with time (345 feeds from 150 experiments). The line represents 
the best fitting linear regression curve with slope –8.27/year (p=0.01).  
 
Reproducibility of TRA 
 
Reproducibility of TRA was explored by repetitive testing of individual sera. To 
facilitate the comparison of TRA values for individual sera in repeated experiments, 
90% confidence limits were constructed using bootstrapping of observed data (see 
Appendix 5.1). An additional advantage of the bootstrapping method was the 
possibility to limit the TRA values to the range of 0 to 100%. Bootstrapping also 
demonstrated that arithmetic means provide more reliable estimates of values of 
TRA than geometric means (see Table 5.A2). This justifies the use of AM oocyst 
densities The relation between observed TRA and its theoretically determined 90% 
confidence intervals and median (TM-TRA) is depicted in Fig. 5.4. TM-TRA values 
were similar to observed TRA values above 20%. TM-TRA values were higher than 
observed TRA values below 20% as a result of the used bootstrapping method. 
Furthermore, the smaller the TM-TRA value was, the larger its variation. 
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Figure 5.4: Observed TRA of individual feeds of field sera against their theoretical 
90% confidence limits (dots) and median (open circles). Experiments with at least 2 
control feeds and at least 17 dissected mosquitoes per feed were included (n=1092). 
Confidence limits and median value were determined by bootstrapping control feed 
data with the assumption that the effect of TRA is proportional.  
 
In order to determine reproducibility of TRA, TRA values of consecutive feeds of 
individual sera were compared (Fig. 5.5). Data points clustered below 20% (51 
observed, 35.6 expected, p<0.05) and above 90% (36 observed, 11.9 expected, 
p<0.001). This is indicative for reproducibility of high and low level TRA in sera from 
Cameroon and Tanzania. Overlap in 90% confidence intervals of repeated feeds 
was 59.4% (234/394); the random overlapping proportion was 49.0% 
(128962/263312), resulting in a reproducibility factor of 20.4%. Furthermore, TRA 
values showed a small but not significant tendency towards higher results after 
repetition of the feed. 
Thus, TRA can be reproduced with field sera, although the degree of 
reproducibility is modest between experiments. 
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Figure 5.5: Interassay variation of TRA (TRA): repeated measurements of TRA for 
individual field sera (median TRA values based on bootstrap data). Experiments with 
at least 2 control feeds and at least 17 dissected mosquitoes per control, were 
included (248 sera, 394 comparisons). Data points cluster below 20% (n=51) and 
above 90% (n=36). All experiments with averaged control oocyst densities above 
zero were included. 
 
Optimisation of the SMFA 
 
Variability in oocyst densities largely influences the variability of the TRA 
outcomes. Therefore, we tried to limit this variability in oocyst densities by exploring 
different thresholds for oocyst densities in controls (Table 5.1). At a threshold of at 
least 35 oocysts on average in controls the reproducibility was at its maximum 
(44.0%). On the other hand, the proportion of accepted feeds decreased to 62.7%, 
and the proportion of higher TRA values in first feeds was similar (45.1%). Thus, 
TRA values for individual sera are best compared at the condition of thirty-five oocyst 
in controls. 
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Table 5.2: Reproducibility of TRA in field sera from Cameroon and Tanzania 
Oocyst density 1 0 10 20 30 35 40 45 50 60 
Feeds accepted  (%) 2 100 95.7 77.6 67.6 62.7 55.2 50.3 47.3 36.7
Data pairs 3 394 359 206 143 102 76 47 41 23 
Bias (%) 4 46.4 45.1* 38.8* 42.0* 45.1 46.1 38.3 29.3* 34.8
Repeat overlap (%) 5 59.4 58.2 60.2 65 71.6 68.4 57.4 53.7 60.9
Random overlap (%) 6 49 49.6 49.8 49.7 49.2 51 51.9 51.7 51.7
Reproducibility (%) 7 20.4 17.1 20.7 30.5 44 35.6 11.5 4.1 19 
 
1 minimum oocyst density (AM) in control mosquitoes  
2 proportion of feeds accepted based on single tested feeds 
3 number of data pairs analysed 
4 proportion of sera that had a higher TRA value at the first measurement, Sign test,* p <0.05 
4 proportion of repeated feeds of the same test serum with overlapping 90% confidence intervals 
5 proportion of feeds of different test sera with overlapping 90% confidence intervals  
6 proportion of repeated feeds with overlapping confidence intervals corrected for random overlap 
 
Comparison of TRA values within experiments 
 
A higher reduction in variability of TRA values was observed by comparing feeds 
within experiments (Fig. 5.6). Feeding of 10 sera was repeated three times within an 
experiment. Feed pairs of oocyst densities showed a high correlation in repeated 
feeds (r=0.843, p<0.001). Furthermore, reproducibility of TRA values was high 
(61.1% = (24/30-0.486)/(1-0.486)). Thus, the most efficient way to compare TRA 
between individual field sera was to compare sera within one experiment.  
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Figure 5.6: Intra-assay variation of TRA (TRA): pairs of repeated measurements of 
TRA per individual field sera within one experiment (median TRA values based on 
bootstrap data). Experiments with 3 control feeds and 20 dissected mosquitoes per 
control (10 sera, 30 comparisons, r=0.843, p<0.001). All experiments with averaged 
control oocyst densities above zero were included. 
 
 
Discussion 
 
This study evaluates the SMFA (136, 161) as the biological assay of choice for 
the determination of TRA in human serum, especially 1) to study the epidemiology of 
transmission reduction, and 2) to evaluate the induction of transmission blocking 
activity by a transmission blocking vaccine (170, 171). The main obstacle appearde 
to be the observed high variability of the TRA outcome. It is crucial to obtain a 
substantial reduction of this variability. In this study we show that the best approach 
for the determination of TRA is to reduce variability 1) by inclusion of experiments 
with at least 35 oocysts per mosquito in control feeds, or 2) by comparing sera within 
an experiment. We did not have sufficient data available to establish the variability of 
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TRA combining both approaches. Nevertheless, we expect that the combined 
approach will further improve the measurement of TRA. 
The SMFA yielded highly variable TRA, despite extensive control of the 
experiments. The production of gametocytes was standardized, and their quality 
assessed by a number of analyses: 1) a threshold for gametocyte density, 2) the 
level of maturation (stage V), 3) the sex ratio of gametocytes, 4) the quality of male 
gametes by exflagellation assays, and 5) infectivity to mosquitoes by prefeed. 
Experimental feeding was performed when prefeed yielded at least 100 ookinetes 
per mosquito. With these measures, it was possible to standardize the number of 
infectious gametocytes in the feeds, but as shown in this study there was a 
considerable variability in oocyst densities. The variation was much larger between 
experiments as compared to replicate feeds within experiments. Reducing variability 
in oocyst densities by setting a threshold at 35 oocysts gave a sub-optimal condition 
for the measurement of TRA, with a maximum reproducibility. Time lapse was found 
to be a slight, but consistent, influence in the experiment. Further analysis revealed 
that this bias was mainly explained by a discrepancy in TRA results when feeds were 
repeated atlarge time intervals. It is not clear what caused this increase in TRA 
values. It cannot be explained by the slight decrease of average densities in controls 
over time (Fig. 5.3), as this would result in a decrease of TRA values. A possible 
explanation is that the maturity of gametocytes might have been sub-optimal in the 
later feeds; Lensen et al. (176) showed previously that the infectiousness of 
gametocytes to mosquitoes depends on a narrow range in the age of gametocytes. 
We are currently investigating if storage in freezers or repeated thawing of serum 
samples may have caused an increase in TRA. 
The SMFA is a laboratory technique to feed mosquitoes on cultured parasites in 
order to determine TRA in sera. Alternative bioassays that are used in field settings 
are mosquito feeding 1) on the skin of parasite carriers (100, 103, 129-131), or 2) 
through a membrane on blood from gametocyte carriers (DMFA, DMFA), (94, 131). 
Skin feeding reflects infectivity of parasites in individual subjects, while transmission 
blocking immunity may be determined by membrane feeding by comparing 
autologous plasma/serum and non-immune donor serum in the feed. Bonnet et al. 
showed a strong correlation between skin feeding and DMFA(133). Mulder et al. 
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showed that TRA results in DMFA and SMFA correlated modestly, and the 
calculated prevalence of transmission reducers was comparable(94). Furthermore, 
sexual stage surface antigens involved in transmission reduction (Pfs48/45, Pfs230 
and Pfs25) show limited variation. This suggests equivalence of DMFA and SMFA 
for reproducibility of TRA. SMFA is preferable though, because it allows for more 
extensive standardization, for the repetition of experiments and for the study of TRA 
in blood samples without gametocytes. 
Most of the research groups involved in transmission reduction compare oocyst 
densities (136, 177-180), whilst some focus on oocyst prevalences (164, 181) or 
sporozoite prevalences (100). Oocyst densities of P. berghei tend to follow a 
negative binomial distribution, approaching a Poisson distribution at high levels (164, 
181). Therefore, the variability of oocyst densities is generally reduced using 
geometric means (164, 177, 181). However, uninfected mosquitoes bias the 
outcome. In our experimental set up, high oocyst densities were selected using the 
SMFA, to prevent bias by negative feeds. Furthermore, we observed a large 
variation (CV>1) in oocyst distributions of P. falciparum in experimental infections. 
Rising oocyst density resulted in a decrease of variation. These observations 
suggest that oocysts of P. falciparum might follow a negative binomial distribution in 
our laboratory set up. Nevertheless, the observed number of non-infected 
mosquitoes is higher than would be explained by a negative binomial distribution of 
oocysts. However, the distribution of oocysts is of limited value for the determination 
of TRA using the described bootstrapping method, because bootstrapping makes no 
assumption based upon the type of distribution (see Appendix 5.1).  
TRA is calculated by determining the ratio between oocyst densities (178) or 
infection rates (179), and is sometimes categorized (136, 180). This makes 
comparison of results between research groups difficult, although the major 
components of experimentation are similar. Our approach takes advantage of the 
experience of the different groups, and the additional validation using repeated 
experiments with field sera. For example, we explored an alternative for the use of 
geometric means of oocyst densities in the calculation of TRA. We confirmed that 
variability in oocyst densities reduced by using geometric instead of arithmetic 
means in our study. Nevertheless, TRA values were less variable and less biased 
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with arithmetic means of oocyst densities than with geometric means (see Appendix 
5.1). In addition, variation in oocyst densities in test and control feed was similar, 
although test feeds had lower oocyst densities than control feeds. 
Ponnudurai (161) showed previously that transmission blocking MoAbs may give 
either consistently high (>90%) or decreasing TRA values in experiments with 
decreasing oocyst densities. Recently, two groups confirmed the observation of 
consistently high TRA values with either human sera or MoAbs against Pfs48/45 
(see Chapter 6) and Pfs25 (Miura, unpublished observations). In the first study, it 
was also observed that samples with intermediate TRA levels (<90%) showed 
enhanced variation in TRA. Both studies showed a proportional reduction in TRA 
after dilution of serum or MoAbs. 
In the laboratory, the variability of TRA may be reduced by selecting experiments 
with high oocyst densities, but oocyst densities are usually low in nature. Billingsley 
et al. showed previously that oocyst densities for any mosquito did not exceed 24 in 
an endemic area in Tanzania (181). That is below the established minimum 
requirements for the SMFA. Furthermore, the prevalence of infected mosquitoes in 
that study was 19% (with a huge variation). With respect to endemic malaria in its 
natural situation, it is difficult, however, to reach statistical significance for differences 
in oocyst densities and prevalences of infected mosquitoes (164, 181). Although the 
high numbers of oocysts per mosquito in the SMFA do not reflect the natural 
situation, the proportionality of TRA allows for its comparison between sera.  
As became apparent from our study, comparison of TRA values within 
experiments considerably limits the effect of variability. Therefore, it is recommended 
that factors that may influence TRA (e.g. transmission blocking vaccines, age, 
gametocyte density, monoclonal antibodies) should be compared within 
experiments. Finally we conclude, that the SMFA is appropriate for the study of TRA 
under the recommended conditions, both in experimental and in epidemiological 
settings. 
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APPENDIX 5.1. Estimation of the sampling error associated with calculating 
transmission-blocking activity from membrane feeds 
 
 
This appendix describes a bootstrapping method for calculating the most likely 
TRA and its confidence limits based upon the distribution of oocysts per mosquito in 
the control feeds described in the accompanying paper. This procedure addresses 
variability resulting from the distribution of oocysts in mosquitoes but does not 
address other sources of intra-experiment variability.  
 
Simulation analysis of maximum probability TRA and confidence limits 
Bootstrap data set:  
 
The average oocysts in all control mosquitoes from a single feeding experiment 
were calculated and feeding experiments were ranked in order of this average. 
There were 201 feeding experiments, with 466 control feeds. Data from individual 
mosquitoes from five consecutively ranked feeding experiments were pooled to give 
forty groups of mosquitoes with progressively higher average oocysts counts. A 
series of simulations was done, each simulation with a progressively increasing 
theoretical TRA (ranging from 0 to 100%). For each theoretical TRA, a simulated 
control feed and test feed were generated as follows: twenty, forty or sixty 
mosquitoes (to simulate one, two or three control feeds, respectively, per feeding 
experiment) were picked at random from one of the forty data sets and the 
experimentally determined oocyst number of each of these was used to calculate the 
arithmetic mean oocysts. This would be the control average for this simulation. A 
further twenty mosquitoes picked from the same data set formed the test group. The 
simulated number of oocysts for each of the test mosquitoes was chosen from the 
actual experimentally derived number of oocysts in each test mosquito, decremented 
using a binomial random number generator, with probability = 1-TRA/100. The 
arithmetic mean of simulated oocyst numbers in each of the 20 test mosquitoes was 
calculated.  
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The calculated TRA for this simulated experiment was calculated as:  
100* (mean control oocysts – mean test oocysts)/mean control oocysts. 
The calculated TRA, the theoretical TRA and the simulated mean control oocysts 
constitute one datum. 
Because of how the data sets were constructed, there is an equal probability that 
the controls for an actual feed will lie in any of the 40 input data sets. Implicit in this 
simulation is the assumption that transmission-blocking activity is independent of the 
potential oocysts load per mosquito.  
However, it makes no assumption with respect to the frequency distribution of 
oocysts per mosquito. If the variance in the number of oocysts per control mosquito 
resulted wholly from the random nature of the distribution of oocysts per mosquito 
and not from feed to feed variation (see below), then since the forty pools of 
mosquitoes were assembled from several feeds, confidence limits of TRA derived 
from these simulations are expected to be slightly overestimated. 
Tables linking the observed TRA to the most likely theoretical TRA and its 
confidence limits were constructed as follows: For each of the forty input data sets, 
300 simulations were done for theoretical TRA, increasing from 0% to 99% in 1% 
increments. The 1.2 million simulated data sets were sorted into twenty groups of 
increasing average observed oocysts per control mosquito to give a theoretically 
equal frequency distribution per group. As the actual distribution reflects the 
stochastic nature of the simulation, the exact numbers varied per group and so each 
group was randomly trimmed to contain exactly 40,000 sets of data. Each of these 
was sorted into forty sub-sets of increasing observed TRA and each sub-set sorted 
according to the theoretical TRA used. Each sorted data set was then used to fit an 
association between observed TRA and the most likely theoretical TRA, and to 
determine the confidence limits on the estimate of TRA (i.e. the 90% confidence 
limits are determined from the 51st to the 950th value of theoretical TRA in the sorted 
set.  
Over most of the range of values, the observed TRA and the underlying 
theoretical TRA are linearly correlated with a slope of one. However, for low values 
of TRA, the relationship markedly curves. At the extreme are negative observed TRA 
values (i.e. where the oocysts counts in test mosquitoes happen, by chance, to be 
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greater than in the control mosquitoes). In this model, all of these test feeds must 
have arisen from samples where the actual TRA was zero or slightly positive, and 
then these simulations predict, as expected, that the most likely true TRA for an 
observed negative TRA will be more than zero (accompanying paper, Fig. 5.4).  
For all data sets, the median and 90% upper and lower limits could be 
adequately fitted to a four parameter exponential curve: 
 
TRAt = a + b/(1 + e-(TRAo – c)/d)     [5.1] 
 
For data sets where the observed number of oocysts in the control mosquitoes 
was more than twenty, (a total of 33 sets, corresponding to mean oocysts counts 
ranging from twenty to 190 and with one, two or three control feeds per experiment), 
were fitted to a parabolic surface to give the following empirical equations: 
 
aL = p1L + p2Ln + p3Lo + p4Ln2 + p5Lo2    [5.2] 
am = p1m + p2mn + p3mo + p4mn2 + p5mo2    [5.3] 
aU = p1U + p2Un + p3Uo + p4Un2 + p5Uo2    [5.4] 
 
Where n is the number of control mosquitoes dissected (twenty, forty or sixty) 
and o is the average number of oocysts per mosquito observed in control 
mosquitoes. Subscripts L, m and U refer to the parameters for the lower, median and 
upper limits of the estimate of theoretical TRA. Similar equations describe b, c and d. 
The parameters are listed in Table 5.A1. 
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Calculation of TRA 
 
Three methods have been used in the literature (Lensen, 1996) to calculate ratio 
of infectivity of mosquitoes in the presence and absence of immune sera, and hence 
the TRA {TRA= 100*(1- ratio infectivity)}. These are: 
 
1. Ratio of arithmetic mean oocysts per mosquito (Σot/n)/(Σoc/m) 
2. Ratio of geometric mean oocysts per mosquito ((Πot)1/n)/((Πoc)1/m) 
3. Ratio of average natural log of number of oocysts per mosquito  
(Σ(ln(ot))/n)/(Σ(ln(ot))/n) 
 
Where n and m are the number of test and control mosquitoes dissected in each 
experiment and where ot and oc are the number of oocysts on individual test and 
control mosquitoes, respectively.  
 
The TRA calculated using method three depends on the number of oocysts per 
mosquito in control feeds. This is contrary to experiments that show that the TRA of 
a given antibody preparation is not significantly different for feeds covering a wide 
range of oocysts per mosquito (Miura, personal communication) and will therefore 
not be further considered.  
 It can be shown mathematically that provided an antiserum acts to 
independently reduce the probability of the formation of oocysts and there are no 
mosquitoes with no oocysts, true TRA calculated for an infinitely large sample will be 
the same for both method one or two. However, in practice, the two methods may 
not give equally good estimates of TRA for two reasons. First, when any mosquito in 
a feed has no oocysts, then the geometric mean cannot be used. To avoid this 
problem, a modified form of the GM is normally used (GM (oocysts +1) -1). The 
addition of 1 to each sample biases the estimate, especially for high values of TRA 
or for feeds where there are appreciable numbers of uninfected mosquitoes. Second, 
where there is an unusual distribution of oocysts, it is not clear if both the arithmetic 
and geometric means provide equivalent estimates of the true population mean.  
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To investigate the preferred method of calculating TRA, a series of 
simulations was done using bootstrap data sets derived from feeds with an average 
of approximately 10, 20, 40, 80 and 190 oocysts per mosquito in control mosquitoes, 
for 30%, 60% and 90% theoretical TRA and for 20 mosquitoes in both test and 
control feeds. Estimated TRA was calculated using arithmetic and geometric means 
for each simulation. The simulation was repeated 1,000 times for each input 
combination and the mean and standard deviation of the estimated TRA was 
calculated. 
As shown in Table 5.A2, as judged by the standard deviation of the repeat 
estimates of the TRA, calculation of the TRA using the geometric mean gave a 
substantially poorer estimate than that calculated by the arithmetic mean. It also 
tended to underestimate the TRA, especially for lower true TRA and for lower 
numbers of oocysts per control mosquito. Therefore, using the arithmetic mean is 
recommended for calculating TRA and this method was used in the accompanying 
paper. 
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Table 5.A1: Parameters for calculating maximum likelihood values of TRA and 
confidence limits from observed value of TRA, the observed number of oocysts per 
mosquito and the number of control mosquitoes dissected per feed 
 p1 p2 p3 p4 p5
aL 2.982 -0.0758 -0.0538 4.85E-04 1.03E-04 
bL 144.8 -0.159 -0.3641 6.96E-04 1.62E-03 
cL 95.36 -0.2682 -0.2682 1.82E-03 9.39E-04 
dL 13.15 0.0964 0.0316 -8.54E-04 -4.07E-05 
am 15.41 -0.269 -0.1733 1.93E-03 4.81E-04 
bm 125.9 0.1758 0.0234 -1.14E-03 1.56E-04 
cm 82.01 -0.2221 -0.1765 1.71E-03 6.30E-04 
dm 26.48 0.0856 0.0133 -6.98E-04 -1.06E-05 
aU 41.2 -0.4842 -0.3594 3.22E-03 1.06E-03 
bU 94.12 0.3343 0.4142 -7.01E-04 -1.10E-03 
cU 77.73 -0.3479 -0.1128 3.35E-03 4.19E-04 
dU 40.33 -0.0557 -3.75E-04 9.90E-04 7.27E-05 
Parameters a, b, c and d are calculated with parameters p1-p5, the number of dissected control 
mosquitoes and the average oocyst density in controls (using equation [2] and similar equations). 
Parameters aL, bL, cL and dL describe the lower 90% confidence limit for TRAt (equation [1]). Median 
TRAt is calculated with aM, bM, cM and dM and parameters aU, bU, cU and dU describe the higher 90% 
confidence limit for TRAt. 
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Table 5.A2: Estimated TRA and standard deviation (s.d.) for TRA calculated using 
arithmetic (AM) or geometric means (GM) of oocyst densities 
TRA 30% TRA 60% TRA 90% Oocysts/ 
control 
Calculation 
method Mean S.d. Mean S.d. Mean S.d. 
10 AM 26.2 34.3 56.0 19.7 88.4 7.4 
20 AM 26.2 29.4 58.3 14.7 89.0 6.6 
40 AM 24.6 35.8 57.6 16.0 88.6 6.8 
80 AM 28.8 18.6 59.5 9.0 89.1 6.0 
190 AM 28.1 19.6 59.3 8.8 89.7 2.3 
10 GM 22.9 34.1 49.2 26.4 83.6 12.6 
20 GM 22.4 33.8 52.2 24.7 84.4 14.6 
40 GM 23.5 35.6 52.9 25.3 83.1 14.1 
80 GM 28.0 26.8 57.9 16.7 85.4 14.5 
190 GM 25.9 30.2 57.0 19.2 88.4 4.8 
 
 
 
Acknowledgements 
 
The authors want to thank Ikupa Akim and Chris Drakeley for the collection of 
Tanzanian sera. We are grateful to the inhabitants of the Dakar district in Yaoundé 
and the participants in Ifakara for their appreciated cooperation. Mike van der Kolk 
and Sake de Vlas are supported by WOTRO grant WM93-350. WHO TDR Research 
Capability Strengthening Grant 970781 funded the Cameroon project. The 
Tanzanian project was funded by WHO TDR grant 950428. 
 
 
 85
Chapter 6. Quantification of P. falciparum  TRA by the SMFA 
 
Mike van der Kolk1,2,3*, Sake J. de Vlas4, Marga van de Vegte-Bolmer1, Wijnand M. 
C. Eling1, Christian Boudin2,3 and Robert W. Sauerwein1 
 
1Radboud University Nijmegen Medical Centre, MMB 268, P.O. Box 9101, 6500 HB Nijmegen, the 
Netherlands  
2Institut de Recherche pour le Développement, rue La Fayette 75480 Paris cedex 10, Paris, France 
3Organisation de Coordination pour la lutte contre les Endémies en Afrique Centrale (OCEAC), 
Laboratoire de Recherche sur le Paludisme, BP 288, Yaoundé, Cameroun 
4Department of Public Health, Erasmus MC, University Medical Centre Rotterdam, PB 1738, 3000 DR 
Rotterdam, the Netherlands 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Submitted for publication to Parasitology. Reprinted with permission from Cambridge 
University Press. 
Quantification of TRA 
 
 86
Abstract 
 
The capacity of sera to reduce transmission of P. falciparum  from humans to 
mosquitoes can be determined in the SMFA. The objective of this study was to 
evaluate TRA as a quantitative measure. Serial dilutions of anti-Pfs48/45 and anti-
Pfs25 monoclonal antibodies and of immune serum showed a dose-dependent 
reduction of TRA. In addition, TRA showed a weak negative association with 
gametocyte density in the SMFA. Our data provide evidence that TRA assessed in 
the SMFA can be used as a quantitative measure for reduction of transmission. 
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Introduction 
 
Antibodies that are naturally acquired or experimentally induced by sexual stage 
antigens can reduce malaria transmission. Natural transmission reducing antibodies 
are induced by gametocytes in the human host and are ingested by the mosquito 
together with the gametocytes. In the mosquito, these antibodies may arrest the 
development of gametes to oocysts. The SMFA can determine the effect of 
antibodies on transmission. In the SMFA, A. stephensi mosquitoes are fed with a 
mixture of serum, cultured P. falciparum  gametocytes and red blood cells. TRA is 
defined as the proportional reduction of oocyst density in feeds with test sera 
compared to control sera. Several studies show the presence of TRA in sera from 
different endemic settings (94, 100, 108, 117, 130, 131). In particular, antibodies 
against Pfs230 (89, 94, 116, 124, 182) and Pfs48/45 (88, 94, 122, 124, 182) have 
been shown to be associated with transmission reduction. The associations between 
transmission reduction and sexual stage antibodies have been confirmed with a 
panel of monoclonal antibodies against different Plasmodia (117, 178, 183, 184). In 
addition, there are equivocal observations of the effect of gametocyte densities on 
the association between transmission reduction and sexual stage antibodies (161). 
However, these studies show qualitative rather than quantitative effects of antibodies 
on transmission.  
We recently evaluated the SMFA, improved the calculation method for TRA and 
adapted the experimental conditions of the SMFA test (185) (Chapter 5). TRA has 
been shown to be reproducible, in particular by repeated measurements with 
individual sera. The objective of this study was to evaluate TRA based on the SMFA 
as a quantitative measure for the activity of field samples and transmission blocking 
antibodies. 
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Materials and methods 
 
Endemic sera and anti-sexual stage monoclonal antibodies  
 
Serum was obtained from 18 gametocyte carriers identified by Giemsa stained 
thick smears. We distinguished two groups: 1) endemic gametocyte carriers from 
Yaoundé, Cameroon (n=12) (173); and 2) expatriates living in malaria endemic areas 
in Africa or Asia for several years (n=6) (94). Gametocyte carriers of 5 years and 
older were informed about the purpose of the study and included after consent was 
obtained from their parents or guardians. Blood (2 ml) was drawn by venupuncture 
into Vacutainer® tubes without anticoagulant at time of enrolment and occasionally 
during home visits. Serum was harvested and stored at –20oC. Carriers of asexual 
parasites were treated with Fansidar (25 mg sulphadoxine and 1.25 mg 
pyrimethamine per kg body weight). The National Ethical Clearance Committee in 
Cameroon approved the project. 
Monoclonal antibodies (MoAbs) against sexual stage antigens were previously 
described (93). Anti-Pfs25 (32F81) was raised in mice and anti-Pfs48/45 epitope 5 
(85RF45.5) in rats.  
 
SMFA 
 
TRA of monoclonal antibodies and human sera was determined in the SMFA as 
was previously described (185). In short, cultured P. falciparum  NF54 gametocytes 
were fed in the presence of red blood cells and heat inactivated (30 min 56oC) non-
immune human donor serum (NHS). A parasite culture with 0.5-1.0% gametocytes 
and 2% haematocrit was resuspended and centrifuged with 150 μl packed red blood 
cells. The cell pellet was resuspended with 150 μl serum and fed in 300 μl aliquots 
(52% haematocrit) to 50 laboratory reared A. stephensi mosquitoes. Undiluted feeds 
contained an estimated number of 800-1 600 gametocytes/μl, or 2-5,000 
gametocytes per mosquito feed of three μl (186). SMFA experiments usually 
consisted of twenty independent feeds. Oocysts were counted after seven days in 
twenty mosquitoes per feed. TRA is the measure for the reduction of oocyst numbers 
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in test feeds (with test serum or MoAbs) compared to control serum, expressed as 
the proportion of oocysts reduced in the test feed compared to the control feed. Data 
were statistically adapted by a bootstrapping technique to fit TRA in a range of 0 to 
100% (185).  
 
Statistical analysis 
 
Stata 7.0 (Stata Corporation, 4905 Lakeway Drive, College Station, Texas 77845 
USA) was used for longitudinal data analysis (187). This allowed for the 
simultaneous comparison of TRA with different cofactors, like gametocyte density 
and antibody concentration. A major advantage of longitudinal data analysis is the 
possibility to combine series of repeated experiments in a single analysis, thus 
increasing the precision of the comparison. TRA, antibody concentration and 
gametocyte dilutions were not normally distributed; therefore the data were 
transformed to approach normality (logit for TRA, log for concentrations and 
dilutions). We applied longitudinal data analyses (in Stata: generalised estimated 
equation, GEE) accounting for repeated measurements of serial dilutions of the 
same sera, of monoclonal antibodies and of gametocyte suspensions, which were all 
tested in the same SMFA experiments. We considered log antibody concentration 
and log gametocyte dilution as fixed continuous variables (the cofactors of interest) 
in the linear regressions, and the experiment number as the random variable. We 
also compared two dilutions of gametocytes within experiments with gametocyte 
dilution as dichotomous variable.  
 
 
Results 
 
Figure 6.1 shows that TRA of undiluted serum from 18 gametocyte carriers 
ranged from 4.0 to 99.3% (median 55.9%). Dilution of serum in the SMFA test 
resulted in an overall downward trend in TRA with a decrease in 13 sera and no 
change or fluctuations in five sera. Assuming that TRA will follow an inverse sigmoid 
relationship with serum dilution, transformed TRA (logit) and serum dilution (log) 
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would show a linear relationship. GEE analysis showed a strong negative correlation 
of transformed TRA values and serum dilutions (n=59, 18 experiments, β=-1.00, se 
(β) = 0.15, P<0.001). This indicates that TRA consistently decreased with serum 
dilutions from different individuals. In addition, the effect of immune serum on TRA 
was independent of the level of TRA in repeated measurements (TRA>50% vs. 
TRA<=50%) (β=0.197, se (β) = 0.263, P=0.454).  
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Figure 6.1: TRA in serum from individual gametocyte carriers (closed circles: 6 
expatriates, open circles: 12 Cameroonians). Sera were serially diluted (1/1, 1/3, 1/9 
and 1/27). The bold line is the logit adjusted average TRA for all serum samples. 
 
Next, we used monoclonal antibodies (MoAb) to study the quantitative 
relationship with TRA (Figure 6.2). Increase of anti-Pfs48/45 (85RF45.5, Figure 
6.2A) concentration resulted in an overall upward trend in TRA with an increase in 
twenty-four repeated feeds and fluctuations in five repeated feeds. Increase of anti-
Pfs25 (32F81, Figure 6.2B) concentration resulted in an overall upward trend in TRA 
with an increase in seven repeated feeds and fluctuations or decrease in three 
repeated feeds. Higher concentrations of 85RF45.5 were needed than 32F81 to 
obtain similar TRA levels. The association with concentration is weak for both 
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Figure 6.2: TRA in relation to MoAb concentration in SMFA. (A) TRA over a 
concentration range of anti-Pfs48/45 epitope 5 MoAbs (85RF45.5) in 29 SMFAs (91 
repeated and 86 single mosquito feeds, respectively). (B) TRA over a concentration 
range of anti-Pfs25 MoAbs (32F81) in 12 SMFAs (29 mosquito feeds). 
Concentrations were based upon dilution from the highest concentration of MoAb 
and were tested within single SMFA experiments. The bold lines represent the logit 
adjusted average TRA values for all antibody samples. 
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 antibodies, but stronger for 85RF45.5 (n=91, 29 experiments, β=0.907, se (β) = 
0.121, P<0.001) compared to 32F81 (n=29, 12 experiments, β=0.224, se (β) = 0.057, 
P<0.001). These analyses also indicated that the relationship of TRA with both 
MoAbs consistently had a sigmoid pattern. 
Figure 6.3 shows the average logit of TRA at different concentrations of 
85RF45.5 and serial gametocyte dilutions. Logit TRA is used instead of TRA for a 
better overview of the three variables, to show possible parallel lines for different 
gametocyte densities. A linear correlation between logit TRA and log antibody 
concentration would correspond with a sigmoid relationship between antibody 
concentration and TRA, illustrating a dose-response relationship. Start gametocyte 
suspension (1/1 dilution) represents 800-1 600 parasites per μl. There was an almost 
linear trend of increasing logit TRA with increasing log concentration of antibodies 
(>6.25 μg/ml) for all three (1/9, 1/3 and 1/1) gametocyte dilutions. GEE analysis (136 
measurements within 12 experiments) showed that TRA was strongly associated 
with antibody concentration (log transformed antibody concentration: βAb=1.261, se 
(β) = 0.046, P<<0.001) and to a lesser extent with gametocyte dilution (log 
transformed dilution of gametocytes: βgtc=0.400, se (β) = 0.107, P<0.001). On 
average, logit (TRA) increased by 0.55 when antibody concentration was doubled, 
and with 0.26 when gametocyte density was halved. When 1/9 and 1/3 gametocyte 
dilutions were used, TRA values largely overlapped for all antibody concentrations. 
In contrast, TRA was consistently lower with undiluted gametocytes. Statistical 
testing showed no significant difference between 1/9 and 1/3 gametocyte dilutions 
(79 measurements within 9 experiments, βgtc=0.142, se (β) = 0.157, P=0.37), but a 
highly significant difference between 1/3 and 1/1 (104 measurements within 12 
experiments, βgtc=0.783, se (β) = 0.192, P<0.001). This means that TRA was 
strongly associated with concentrations of transmission blocking antibodies and to a 
lesser extent with gametocyte density.  
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Figure 6.3: Logit (TRA) in relation to anti-Pfs48/45 epitope 5 MoAb concentrations at 
different gametocyte dilutions (start gametocyte suspension ▲; 1/3 diluted *; 1/9 
diluted ●) in 136 mosquito feeds within 12 SMFAs (90% confidence limits). Logit 
(TRA) values of -2, -1, 0, 1, 2, 3, and 4 correspond to TRA values of about 12%, 
27%, 50%, 73%, 88%, 95% and 98%, respectively. 
 
 
Discussion 
 
This study shows reproducible dose-response relationships of TRA with 
transmission reducing antibodies (anti-Pfs48/45, anti-Pfs25 and immune field sera). 
The dose-response relationship of TRA with anti-Pfs48/45 antibodies is reproducible 
at different gametocyte densities. Furthermore, TRA decreases at increasing 
gametocyte densities. The effect of anti-Pfs48/45 antibodies on TRA is larger 
(threefold on a logit-log scale) than the effect of gametocyte density. In addition, TRA 
discriminates modestly for field sera and weakly for monoclonal antibodies (anti-
Pfs48/45, anti-Pfs25). TRA shows variability to a certain extent, which is larger 
between than within experiments. The reproducibility of TRA in repeated 
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measurements justifies the use of TRA as a quantitative measure for the comparison 
of groups of samples with transmission blocking potential. Furthermore, sera are 
better compared quantitatively than qualitatively, because of greater precision and 
greater statistical power.  
This study shows that transmission blockade consistently associates with sexual 
stage antibodies and gametocyte density, whereas preliminary studies with limited 
observations showed no gametocyte dependent association between transmission 
blockade and antibodies (161). We applied the following ameliorations in our study: i) 
an adapted calculation method for TRA (185), ii) a different statistical analysis 
technique allowing for repeated measurement analysis (GEE) and iii) a large number 
of repeated experiments with monoclonal antibodies. TRA shows dose-dependent 
relationships with MoAbs against Pfs48/45 and with immune sera. Possibly, TRA of 
immune sera is determined by the presence of sexual stage antibodies. Previously it 
has been shown that TRA of field sera associates with the presence of sexual stage 
specific antibodies including Pfs48/45 and Pfs230 (88, 89, 94, 116, 117, 124, 182-
184).  
Since TRA is calculated from oocyst densities, it is important to know whether 
gametocytes and oocysts correlate. The number of oocysts is tightly log linear 
related to the number of gametocytes in repeated experiments with dilutions of 
gametocytes (8 experiments, with up to 8 gametocyte dilutions, β=-1.00, se (β)=0.04, 
data not shown). This suggests that the gametocyte-oocyst relationship is 
independent of the density of gametocytes of the same source and that, for instance, 
a ten times higher gametocyte density gives exactly a ten times higher oocyst 
density. Several older studies show a strong but variable association of gametocyte 
and oocyst densities in individual experiments (164, 188). The limited variation in 
oocyst densities in repeated experiments (also shown with P. gallinaceum, (188)) 
and the high variation between the individual experiments suggests that variability in 
oocyst densities is largely explained by the different capacity of gametocytes of 
different sources to produce oocysts.  
Interaction of gametocyte density with antibody concentration is not found 
because the slopes for logit TRA versus log antibody concentration are similar for 
the three gametocyte densities tested. The effect of concentration of anti-Pfs48/45 
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antibodies on logit (TRA) is about three times the –inverse- effect of gametocyte 
density. This means that the effect of doubling the anti-Pfs48/45 antibody 
concentration on TRA can be compensated by gametocyte density, that is six times 
higher. Thus, TRA is primarily proportional to antibody concentration but also to 
gametocyte density.  
It should be noted that gametocyte densities in undiluted test suspensions in the 
SMFA are much higher (800-1 600/μl) than in gametocyte carriers in areas with 
natural transmission. Malaria patients in endemic areas in Kenya and Nigeria for 
instance, typically carry on average 22-40 gametocytes per μl blood (189, 190), 
which is a factor of approximately forty times lower than the experimental densities. 
The lowest gametocyte density we use is about 90/μl. Because of the negative 
association of TRA with gametocyte density (at densities between 90 and 1600/μl), 
TRA is likely higher at densities below 90/μl. Therefore; TRA based upon natural 
gametocyte densities may be higher than measured in the SMFA thus far. 
We conclude that TRA based on the SMFA is a reproducible quantitative 
measure for immune sera and monoclonal antibodies. Two specific aims for the use 
of TRA are the evaluation of 1) dose-response reactions, and of 2) transmission 
blocking immunity in longitudinal surveys. Therefore, antibodies and field sera can 
be compared in concentration and time series. Repeated measurements will 
certainly contribute to the robustness of such studies. TRA might further prove to be 
a valuable tool in the evaluation of transmission blocking vaccines.  
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Abstract 
 
Transmission of P. falciparum  from man to mosquito can be affected by 
human sera. Whereas serum dependent reduction of transmission has been shown 
to be reproducible, there is limited evidence of enhancement of transmission. We 
aimed to assess the prevalence and reproducibility of transmission enhancement 
(TE) by human sera from different geographic areas (n=642), in comparison with the 
capacity for transmission reduction (TR). The overall prevalence of TE (7%) was 
lower than that of TR (48%), and its effect generally weaker. Both TE and TR were 
reproducible in repeated measurements. TR but not TE showed a significant 
association with the presence of serum antibodies against Pfs48/45 and a non-
significant trend to the presence of anti-Pfs230 antibodies.  
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Introduction 
 
The effects of human serum activity on malaria transmission can be measured by 
mosquito feeding on human blood in experimental settings. We have previously 
demonstrated the reproducibility of TRA (185), and transmission reduction (TR) has 
been shown in several studies of both P. falciparum  and P. vivax (94, 118, 191). TR, 
furthermore, has been demonstrated in membrane feeding experiments with serially 
diluted transmission reducing monoclonal antibodies (183). The above studies 
confirm unequivocally the existence of TR as a measurable and reproducible 
phenomenon.  
It has also been suggested that transmission may be enhanced by human sera, 
possibly contributing to the force of transmission. Some studies have indeed 
reported transmission enhancement (TE) effects of human sera (89, 108, 117, 178, 
192). However, those studies used small sample sizes with a variety of Plasmodium 
species, and did not demonstrate the reproducibility of TE. There is, therefore, only 
limited evidence of the existence of TE. 
Pfs48/45 and Pfs230 are sexual stage specific antigens and targets for TR 
antibodies (117). The presence of antibodies in endemic sera against both antigens 
has previously been shown to be associated with TR activity (88, 89). Previous 
publications show that there is some indication that TE associates with low titers of 
anti- Pfs48/45 and Pfs230 (89, 117, 183).  
The objective of this study was to assess the prevalence and reproducibility of 
TE in human sera from residents of areas where P. falciparum malaria is endemic. 
Thus, a large number of sera from such individuals were tested either once (n=423) 
or repeatedly (n=219) in a standard membrane-feeding assay. We determined (1) 
the frequency and magnitude of TE and TR, and (2) the extent to which TE and TR 
are reproducible by comparing the outcomes of repeated measurements with 
individual serum samples. Furthermore, we explored whether TE, like TR, 
associated with the presence of anti-Pfs48/45 or anti-Pfs230 antibodies.  
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Materials and methods 
 
Human sera 
 
Sera from gametocyte carriers in Cameroon (n=458), Indonesia (n=48) and 
Tanzania (n=136) were collected as previously described (173, 193, 194). Briefly, 
sera from Tanzania were from subjects with malaria symptoms, taken before 
treatment, whereas those from Cameroon and Indonesia were from asymptomatic 
individuals. Previous history of malaria drug administration was not recorded. The 
age of the subjects ranged from two to seventy, and the gender ratio was 315 males 
/ 327 females. The relevant National Ethics Committees in the three countries 
approved the studies.  
SMFA 
Mosquitoes were fed with a mixture of human red blood cells, in vitro cultured 
gametocytes and human serum according to the standard protocol previously 
described in detail (185). Transmission enhancement (TE) and reduction (TR) were 
qualitatively determined by comparing, within experiments, the oocyst densities in all 
mosquitoes per experimental feed with those of all mosquitoes of control feeds. 
Minimal criteria for inclusion of the results of a given SMFA in the overall analysis 
were 17 mosquitoes per experimental feed and 34 control mosquitoes (i.e. 2 control 
feeds) per experiment (185). 
 
ELISA for anti-sexual stage antibodies 
 
A capture ELISA for assessment of anti-Pfs48/45 antibodies using rat 
monoclonal antibody (MoAb) 85RF45.2b, was performed as previously described 
(88), with an extra blocking (5 (wt/vol) low-fat dry milk (Marvel, Premier International 
Foods Ltd, Spalding, Lincs, United Kingdom) in phosphate buffered saline, pH 7.4 
(PBS), and washing step (3 x PBS+0.05% Tween20) after gametocyte incubation. 
Sera (n=169) only from Cameroon were tested at a dilution of 1/100, next to 4 
negative controls and a serially diluted positive control (1/100-1/12800). Peroxidase 
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reaction was assessed with TMB (0.25 mM 3,3’, 5,5’-tetra-methyl-benzidine, 0.7 mM 
H2O2 in 0.1 M sodium-acetate pH 5.5). Sera were considered positive for anti-
Pfs48/45 antibodies, if their OD450 was higher than the average of the negative 
controls plus 2 standard deviations.  
Anti-Pfs230 seropositivity was assessed in 236 sera from Cameroon in a similar 
ELISA, in which wells were coated with 50 μl of 5 μg/ml anti-Pfs230 rat MoAb 
6D7.F(ab)2. A second blocking step after gametocyte extract incubation and the 
successive triple wash was omitted.  
Statistical analysis 
Since their distributions were skewed to the left, oocyst densities were 
normalised by log transformation after addition of one to allow for zero values. We 
measured the magnitude of serum effects by Effect size (ES) (195), which is the 
standardized difference between the mean oocyst densities in control (Mc) and 
experimental feeds (Mexp):  
 
ES = [Mc – Mexp] / δ      (Equation 7.1)  
 
where δ is the average standard deviation of control and experimental oocyst 
densities.  
 
TE is defined as a significantly higher oocyst density with test [endemic] serum 
compared to control serum (ES<-0.2). Similarly, TR is defined as a significantly lower 
oocyst density with test [endemic] serum (ES>0.2). We assumed weak effects if 
0.2≤|ES|<0.5, intermediate effects if 0.5≤|ES|<0.8 and strong effects if |ES|≥0.8. Sera 
that were neither enhancing nor reducing, |ES|<0.2, were considered to show no 
significant effect (NSE). The value of 0.2 for |ES| would correspond approximately to 
a P value of 0.05 if one-sided Student t tests were performed.  
In total, 642 sera were tested in the SMFA, 423 once, 167 twice, 45 three times 
and 7 four times. From sera that were repeatedly measured, only the first 
measurement was used for assessment of TE and TR frequencies. For repeated 
experiments 219 (167 + 45 + 7) sera were available. All possible (344 = 167 + 3x45 
Transmission reduction and enhancement 
 
 101
+ 6x7) feed pairs per serum were included and ordered according to to date of 
experiments. All degrees of effects (weak, intermediate and strong) TE or TR were 
combined for analysis of reproducibility. 
The Chi squared test was applied for comparisons of proportions. Fisher’s exact 
test was applied to adjust for low expected frequencies. Covariates were tested 
through logistic regression, and their effects represented by odds-ratios with 95% 
confidence intervals (CI). All statistical analyses were performed using the SPSS 
12.0 software package. 
 
 
Results 
 
The presence of TE and TR was determined in 642 individual sera using effect 
size measurement. TE was present at a lower prevalence compared to TR (Table 
7.1). In total, 45 (7%) sera enhanced and 311 (48%) reduced transmission. Where 
TE occurred, the effect was usually weak (41/45 = 91%), while TR, when present, 
was generally much stronger, with a weak effect in only about half (166/311 = 53%) 
of the cases. 
We further evaluated the reproducibility of TE and TR in 219 sera (Table 7.2). 
This serum set was representative of all sera, considering that the distribution of TE 
and TR is approximately equal in Tables 7.1 and 7.2. It is, however, noticeable that 
the proportion of samples displaying TE was more than double in the second 
measurements (39/344) compared to the first measurements of the same sera 
(18/344) (P=0.004). SIx of 344 feed pairs showed TE in both measurements, 
whereas two would be expected if TE were a random event (P=0.01). In comparison, 
the prevalence of TR was similar in the first and second feeds of all feed pairs 
(P=0.3). 101 of 344 feed pairs showed TR in both measurements, whereas 82 would 
be expected if TR were a chance occurrence (P<0.001). Strong TR effects (ES > 
0.8) were observed reproducibly in 23 samples, significantly more than the seven 
expected by chance (P<0.001).  
 
Transmission reduction and enhancement 
 
 102
Table 7.1: Frequency of serum effects on oocysts in mosquito infections by 
membrane feeding 
Serum effect* Number of sera Proportion 
Strong TE1 1 0.2% 
Intermediate TE1 3 0.5% 
Weak TE1 41 6.4% 
NSE2 286 44.5% 
Weak TR3 166 25.9% 
Intermediate TR3 53 8.3% 
Strong TR3 92 14.3% 
 
1 TE: transmission enhancement: oocyst density higher in experimental serum compared to control 
serum 
2 NSE: no significant serum effect 
3 TR: transmission reduction: oocyst density lower in experimental serum compared to control serum 
*Effect size is based on Cohen’s effect size measurement (see Materials and Methods). 
 
 
Table 7.2: Reproducibility of serum effects on oocysts in mosquito infections by 
membrane feeding  
  Second feed  
 Serum effect* TE NSE TR Total 
TE 6 (2.0) 7 (7.5) 5 (8.5) 18 
NSE 18 (17.1) 77 (62.8) 56 (71.1) 151 
Fi
rs
t f
ee
d 
TR 15 (19.8) 59 (72.7) 101(82.4) 175 
 Total 39 143 162 344 
 
* Observed and expected (in parentheses) repeated serum effects in 344 paired measurements. The 
expected number of repeated serum effects was calculated if TE and TR would occur randomly. See 
Table 7.1 for explanation of TE, NSE and TR. 
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TR was significantly more prevalent in Indonesian samples (30/48, 63%, OR = 
2.2, 95% CI 1.2-4.0, P=0.01) and Tanzanian samples (83/136, 61%, OR = 2.1, 95% 
CI 1.4-3.0, P=0.0003) than in Cameroonian samples (198/458 = 43%). However, the 
prevalence of TE was comparable in sera from Cameroon (37/458, 8%), Indonesia 
(1/48, 2%, OR=0.3, 95% CI 0.0-1.8, P=0.2) and Tanzania (7/136, 5%, OR = 0.6, 
95% CI 0.3-1.4, P=0.3). Thus, the prevalence of TR but not of TE differed 
significantly according to the geographical source of sera. 
The prevalence of anti-Pfs48/45 antibodies was similar in sera with TE activity 
(5/19, 26%, OR=0.9, 95% CI 0.3-3.0, P=0.9), but significantly higher in sera with TR 
activity (26/57, 46%, OR=2.2, 95% CI 1.1-4.4, P=0.03), compared to sera with no 
specific effects (26/93, 28%). The prevalence of anti-Pfs230 antibodies was similar in 
sera with TE activity (15/25, 60%, OR=1.0, 95% CI 0.4-2.6, P=0.9), and higher, but 
not significantly so, in sera with TR activity (62/91, 68%, OR=1.5, 95% CI 0.8-2.6, 
P=0.2), compared to those without specific activity (71/120, 59%). 
 
 
Discussion 
 
In this study, we provide firm evidence of the existence of transmission 
enhancement (TE) effects that are reproducible in sera from human gametocyte 
carriers living in geographically separated areas of the world. Our findings indicate, 
nevertheless, that TE activity is less frequent and its effect is comparatively weaker 
than transmission reduction (TR). The proportion of sera with anti-Pfs48/45 and/or 
Pfs230 antibodies tended to be higher in those with TR relative to that of sera with 
no transmission-altering activity at all. Such an effect was not observed with regard 
to TE. 
We specifically chose to use sera from gametocyte carriers for the measurement 
of transmission-altering effects in order to maximize the likelihood of detection of 
such activity. For this reason the prevalence of TE and TR derived from our data is 
probably an overestimate of the true prevalence in the general population. TE and 
TR may, like transmission blocking antibodies, fluctuate in time, suggesting that the 
prevalence overestimate will be modest. The lower frequency of TE relative to TR, 
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as consistently seen in our study, is nevertheless likely to be a general phenomenon. 
The distribution of TE and TR in sera from symptomatic (Tanzanian) and 
asymptomatic (Cameroonian and Indonesian) subjects was comparable, which we 
speculate is also likely to be a universal finding.  
The standard antimalarial drug treatment in the three countries, i.e. chloroquine 
and sulfadoxine/pyrimethamine, may either positively or negatively influence 
gametocyte development and transmission (196). We collected sera before drug 
administration, to limit a possible effect of antimalarials on cultured gametocytes in 
the SMFA.  
The prevalence of TE in our study is low compared to that reported in previous 
studies with much smaller sample sizes (5/40 to 3/4 i.e. 12-75%) (89, 94, 108, 117, 
178, 197). In addition, the observed prevalence of TR is in the upper range of 
previously reported prevalences (5/26 to 4/4 i.e. 19-100%). Apart from the possibility 
of reporting or selection bias, these differences in outcome could be due to both 
geographical and technical/methodological differences. The large number of sera 
tested in our study could be expected to provide more accurate estimates. Moreover, 
we evaluated the existence of TE and TR in a large number of repeated experiments 
(219), which allows for a more conclusive statement concerning the validity of TR 
and TE as real phenomena. 
A previous study with four toque monkeys experimentally infected with P. 
cynomolgi showed TR associated with high levels of stage-specific antibodies, 
whereas TE was associated with low antibody levels (197). This suggests that these 
antibodies may act by either promotion (at low concentration) or reduction (at high 
concentration) of transmission. Low titers of antibody with specificity for sporogonic 
stage antigens might promote adherence of male to female gametes, supported by 
low amounts of bound specific antibodies. On the other hand, high titers of such 
antibodies might limit adherence by effectively ‘masking’ the surface of male and 
female gametes (178). The only established specific target antigens for TR 
antibodies in endemic sera are Pfs230 and Pfs48/45 (88, 89, 117). Our study shows 
that reduction of transmission associates significantly with the presence of anti-
Pfs48/45 antibodies and weakly with the presence of anti-Pfs230 antibodies. Thus, 
whereas Pfs48/45 and possibly Pfs230 may be targets for TR in these sera, the 
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target antigens for TE may be different. In contrast, this study (n>100) does not 
confirm an association of TE with low titers of either Pfs230 or Pfs48/45, as was 
observed in previous smaller studies (89, 117, 183). Further studies are needed to 
identify the target antigens for TE, but will be compromised by the low frequency of 
TE and the possible need for low titers of specific antibodies.  
The existence of TE and TR may be important for the force of transmission, 
especially in low transmission areas. The observed frequency and the effect size of 
TR in human sera in this study is considerably higher than TE, suggesting that 
serum effects on transmission will be predominantly determined by TR activity. The 
distribution of serum effects (TR, NSE, TE) in populations with varying levels of 
exposure to plasmodial infections is clearly a subject deserving further research in 
the context of integrated control measures. 
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Abstract  
 
Transmission of P. falciparum  malaria is initiated by sexual stages in the 
mosquito. Anti-Pfs48/45 and anti-Pfs230 sexual stage antibodies that are ingested 
together with parasites can reduce parasite development and subsequently malaria 
transmission. Acquisition of sexual stage immunity was studied in a cohort of 102 
non-immune Javanese individuals migrating to hyperendemic Papua Indonesia. 
Seroprevalence of antibodies against Pfs48/45, Pfs230 and functional TRA were 
measured upon arrival and at 6, 12 and 24 months. Asexual parasitaemias and 
gametocytaemia were assessed fortnightly. TRA and seroreactivity increased with 
the number of P. falciparum infections. The longitudinally sustained association 
between TRA and antibodies against Pfs48/45 (OR 3.74, 95% CI 1.51--9.29) and 
Pfs230 (OR 3.72, 95% CI 1.36--10.17) suggests that functional transmission 
reducing immunity is acquired following limited exposure to infection.  
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Introduction 
 
Successful transmission of P. falciparum  parasites from humans to mosquitoes 
depends on the presence of infectious gametocytes in the circulation, which are 
derived from a small fraction of asexual parasites. After ingestion of the blood meal 
by mosquitoes, fertilization takes place in the midgut, which will ultimately result in 
the generation of infectious sporozoites in the salivary glands. Specific antibodies 
against sexual stages can interfere with fertilization and subsequent sporogonic 
development when co-ingested with the blood meal, as shown in natural and 
experimental infections (94, 115, 161, 198). This TRA is associated with antibodies 
directed against the sexual stage specific antigens Pfs48/45 and Pfs230 (89, 116, 
121, 122). The rate of development and persistence of TRA is largely unknown. 
While it was suggested to be low-grade and rapidly transient (199), persistent TRA 
has also been observed (88). Acquisition of immunity directed against asexual blood 
stage parasites has been intensively studied people migrating from a non-endemic to 
a malaria endemic area (200-204). In these transmigrants, clinical and parasitological 
immunity developed quickly after exposure (202), with evidence of age playing an 
independent role, being inconsistent (194, 200-204). 
The objective of this study is to examine the development of sexual stage 
specific immunity in a longitudinal cohort of Javanese children and adults from non-
endemic Java, following migration to malaria endemic Papua. Antibody reactivity 
against sexual stage specific antigens Pfs230 and Pfs48/45 was determined and 
compared to antibodies against asexual stage antigen glutamate rich protein 
(GLURP) and whole parasite extracts. GLURP-specific antibodies have previously 
been associated with protection against high levels of parasitaemia (205) and clinical 
disease (206-208). The development of sexual stage specific immunity was 
evaluated by detecting circulating antibodies against Pfs230 and Pfs48/45 and by 
assessing functional TRA in the standard membrane-feeding assay.  
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Materials and methods 
 
Study population  
 
The study site was a newly created transmigration village (designated SP2), 
located near the north-eastern coast of Papua, Indonesia. After informed consent, 
healthy volunteer adults between twenty and forty years of age and children between 
six and twelve years of age were included in the study, which was approved by all 
convening scientific and ethical review boards under U.S. Department of Defense 
Protocol # 30820. Subjects were excluded if admitting a history of residence in a 
malaria endemic area during the previous five years. Details on recruitment, follow-up 
and the epidemiology of malaria in this cohort have been described elsewhere (194). 
Enrolment started in 1996 and follow-up ended in 1999. The subjects originated from 
Java and were enrolled in the study within 48 hr of arrival in Papua, Indonesia. 
Malaria transmission in Java has been very low for many decades, typically around 
0.01 malaria cases/1,000 person-years, and focal malaria of hypo-endemic 
transmission was observed (15). In contrast, malaria transmission in Papua is 
perennial and often hyper- to holo-endemic, with incidence rates ranging from 500 to 
5,000 infections/1,000 person-years (14).  
 
Follow up 
 
Malaria episodes were actively detected over a period of 24 months by periodic 
clinical assessments and blood smears. Blood smears were collected at two-week 
intervals or at any time a subject presented him or herself at the clinic with symptoms 
(chills, fever, etc.) suggesting malaria infection. Blood was microscopically examined 
for P. falciparum and P. vivax asexual parasites and gametocytes by Giemsa-stained 
blood films. Parasites were counted against the number of white blood cells. A slide 
was considered negative after examination of 200 microscopic fields, corresponding 
to 1600 to 2400 white blood cells and an estimated diagnostic threshold of five 
parasites per μl. Parasite densities were calculated using a normal density of 8,000 
white blood cells per μl blood. The first episode of symptomatic or asymptomatic P. 
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falciparum malaria was recorded as first infection. Each subsequent P. falciparum 
parasitaemia was classified as a new infection if it occurred more than 28 days after 
directly observed chemotherapy of the previous infection. Sera were collected on the 
day of arrival and after 6, 12 and 24 months at SP2 (2, 5 16). In order to study the 
acquisition of immunity over time, we selected samples from subjects for whom at 
least three samples were available. We selected 51 subjects aged six to twelve 
years and 51 subjects aged twenty to forty years. The incidence of malaria infection 
in these individuals was not different from that of the general population. 
 
Enzyme Linked Immunosorbent Assays 
Antigen preparation. 
 
Mature gametocytes of P. falciparum (NF54 strain) were produced in an 
automated static culture system as described by Ponnudurai et al. (209), isolated 
(115) and stored at -700C until used. NF54 gametocytes were extracted in 25 mM 
Tris-HCl (pH 8.0) supplemented with 150 mM NaCl, 1.0% sodium desoxycholate 
(DOC) and 1 mM phenylmethylsulphonyl fluoride. Centrifugation pelleted insoluble 
debris (13,000g for 5 min at room temperature) and the supernatant provided 
antigen for ELISA’s (whole parasite, Pfs48/45 and Pfs230). 
 
 
Pfs230 and Pfs48/45 capture ELISA 
 
Anti-Pfs230 IgG antibodies were assayed by coating 10μg/ml of anti-Pfs230 
mouse MoAb 63F6D7-F(ab)2 fragments in phosphate buffered saline (PBS, pH 7.4) 
on Sterilin® ELISA plates (PS, ref 53011, International Medical Products B.V., 
Zutphen, the Netherlands). For Pfs48/45, the plates were coated with anti-Pfs48/45 
rat MoAb 85RF45.3. Plates were blocked with 5% (wt/vol) low-fat dry milk (Marvel, 
Premier International Foods Ltd, Spalding, Lines, United Kingdom) in PBS. For 
Pfs230 or Pfs48/45 antigen capture, plates were incubated with gametocyte extract 
(250,000 parasite equivalents/well). Sera (1:100 dilution) were added to the wells 
and incubated for two hr. Bound IgG antibodies were detected by horse-radish-
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peroxidase (HRPO)-labelled goat anti-human IgG (Pierce 31412). Wells were 
washed three times with PBS and subsequently incubated with tetramethyl benzidine 
(TMB) substrate solution for twenty min. The colour reaction was stopped with 4N 
H2SO4, and optical density (OD) read at 450 nm (Anthos 2001 microplate reader: 
Labtec BV). All incubations were carried out at room temperature. All serum samples 
were tested in duplicate with a concurrent positive control and a minimum of four 
negative (Dutch blood bank donor) controls per plate. Sera were considered positive 
if OD exceeded three standard deviations above the mean of negative controls.  
 
Whole parasite and GLURP ELISA 
 
Antibodies against whole parasite extract and GLURP served as markers for 
general anti-parasite and specific asexual stage immunity, respectively. Sterilin ® 
ELISA plates (PS, ref 53011, International Medical Products B.V., Zutphen, the 
Netherlands) were coated overnight with 250,000 parasites per well by diluting a 
stock containing 30x106 parasites/ml in extraction buffer with PBS (as above). After 
blocking with 5% milk/PBS, sera were incubated 2 hr at room temperature (1/100 
dilutions in 0.1%milk-TPBS). Anti-GLURP85-213 antibodies were measured in plasma 
samples by ELISA (87). Microtiter plates (NUNC™ Maxisorp, Nalge Nunc 
International Corp, Life Techn, The Netherlands) were coated overnight at 4°C with 
50 μl of 0.2µg GLURP85-213 /ml final concentration in 0.05 M carbonate buffer pH 9.6. 
After washing, wells were incubated with 2.5 % (wt/vol) milk in PBS. Plasma samples 
were diluted in PBS/0.05% Tween 20/1.25% milk. For the detection of anti- 
GLURP85-213 IgG antibodies, rabbit anti-human IgG peroxidase (Dako, P-214) was 
used 1/10,000 in PBS/0.05% Tween 20/1.25% milk. The remainders of both tests 
were carried out as for Pfs230 and Pfs48/45 described above. 
 
SMFA 
  
Experimental infections of mosquitoes were carried out as previously described 
(136, 172). Three to five-day old, colony-reared A. stephensi were allowed to 
membrane feed on freshly cultured mature NF-54 P. falciparum gametocytes in 
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batches of 50 mosquitoes each in the presence of serum. A maximum of 17 
transmigrant serum samples were compared to three batches of a single (Dutch 
blood bank donor) control serum. Immediately after the feed, non-fed and partially 
fed mosquitoes were removed. Blood-fed mosquitoes were kept at 26°C and 80% 
humidity for seven days. Surviving mosquitoes (>90%) were dissected and oocysts 
counted from extracted midguts. Twenty mosquitoes per batch were examined for 
oocysts. An SMFA experiment was considered valid when in all three control 
batches the percentage of infected mosquitoes was 90% or more. The observed 
TRA of serum was determined as the percentage reduction in oocyst numbers in test 
samples as compared to controls (185). Functional TRA was defined as a minimum 
of 50% reduction in oocysts numbers in the SMFA. Not all sera were analysed in the 
SMFA because of resource limitations. A random sample of individuals was 
therefore selected and all their available serum samples were tested in the same 
SMFA experiment. 
 
Statistical analyses  
 
Analyses focused on the relation between the development of (functional) sexual 
stage specific immunity and cumulative exposure to P. falciparum, quantified as the 
cumulative number of infections with asexual stage P. falciparum parasites. 
Statistical analyses were carried out using SPSS for Windows, version 10 (SPSS 
Inc., Chicago, IL) and Stata 7.0 (Stata Corporation, 4905 Lakeway Drive, College 
Station, Texas 77845 USA). Prevalence of antibodies and functional TRA 
(dichotomous variables) as a function of exposure to asexual P. falciparum parasites 
was tested using multiple logistic regression models by Generalized Estimating 
Equations (GEE). Regression coefficients β were calculated with 95% confidence 
intervals (95% CI). Prevalence was analyzed logit-linked. The number of infections 
was included as a continuous variable and a random effect was included in the 
models to allow for correlations within individuals. Age group (20--40 years vs. 6--12 
years) and number of P. vivax infections were included in the models as covariates. 
Interaction terms were added to the models to assess a possible modifying effect of 
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age on the relation between exposure to infections and the development of 
immunity. 
 
 
Results 
 
The malariometric indices of the study population are presented in Table 8.1. The 
vast majority of individuals experienced at least one episode of malaria, with a 
median number of three infections during the 24-month period of follow-up. While 
prevalence of infection was similar for adults and children, the latter were exposed to 
higher densities of asexual parasites (P = 0.02, Table 8.1). Gametocytes were 
detected in 26% of the children and 29% of the adults with no statistically significant 
difference in gametocyte density. The cumulative number of infections over a six-
month period is presented in Fig. 8.1. At six months, 20% of the 102 migrants had 
experienced two or more infections; at 24 months, this proportion had increased to 
73%. The cumulative number of subjects in whom gametocytes were observed in 
peripheral blood films was 0, 2, 8 and 18 for time points 0, 6, 12 and 24 months post 
migration, respectively.  
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Figure 8.1. Cumulative prevalence of asexual stage infections in a cohort of 102 non-
immune migrants from Java to Papua, Indonesia experiencing one to over four 
infections of P. falciparum  during 2 years of follow-up in the malaria-endemic area. 
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Table 8.1. Characteristics and P. falciparum  malariometric indices of 102 study 
subjects from the SP2 cohort during 24 months of follow-up in Papua, Indonesia 
 Children Adults P-value 
N 51 51  
Age, median (IQR)  9 (8-11) 32 (28-37)  
Number (percentage) of 
individuals infected  
49 (96.0%) 49 (96.0%) 1.0 
Number of infections per person, 
median  (IQR) 
3 (1 - 3) 3 (2 - 4) 0.53 
Asexual parasite density, GM 
(IQR) 
2792 
(879-11962) 
1697 
(520-5920) 
0.02 
Number (percentage) of 
individuals gametocytaemic  
13 (25.5%) 15 (29.4%) 0.66 
Gametocyte density, GM (IQR) 112 
(40-280) 
176 
(48-579) 
0.21 
 
IQR = interquartile range; GM = geometric mean parasite density in parasites/μl for P. falciparum 
asexual parasite or gametocyte carriers only. 
 
Seroreactivity against whole P. falciparum extracts and asexual stage specific 
antigens increased with cumulative exposure (Fig. 8.2A). Antibody prevalence in the 
whole parasite ELISA rose to 98% after two infections and remained high after 
further infections. The prevalences of antibodies against sexual stage specific 
antibodies Pfs48/45 and Pfs230 were also increased after two infections (Fig. 8.2B). 
The proportion of serum samples with TRA gradually rose from 10% (3/29) prior to 
migration, increasing to 27% (3/11) after more than four infections. There was a clear 
association between the presence of gametocytes at the time of sampling and TRA 
(OR 5.22, 95% CI 1.87--14.56). Nevertheless, only 31.3% (10/32) of sera with TRA 
were derived from individuals with patent gametocytaemia at the time (n=9) or prior 
to sampling (n=1). After adjustment for the number of infections, TRA was 
significantly associated with the prevalence of anti-Pfs48/45 antibodies (OR 3.74, 
95% CI 1.51--9.29) and anti-Pfs230 antibodies (OR 3.72, 95% CI 1.36--10.17). No 
statistically significant association existed between TRA and the prevalence of anti-  
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Figure 8.2. Proportion of serum samples with P. falciparum specific antibodies as a 
function of the number of prior P. f. infections. A. Seroreactivity for whole parasite 
(open circles) and asexual-stage specific GLURP (open squares). B. Seroreactivity 
for sexual-stage specific Pfs230 (asterisks) and Pfs48/45 (open triangles), and 
functional TRA>50% (closed circles). For TRA, exactly 20 mosquitoes were 
dissected per serum sample included in the SMFA. The control samples resulted in a 
median number of 21 oocysts (IQR 7--46) per mosquito. Error bars indicate the 
upper limit of the 95% confidence interval. 
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whole parasite (OR 4.21, 95% CI 0.53--33.18) or anti-GLURP (OR 1.90, 95% CI 
0.83--4.34) antibodies. 
In order to adjust for correlation between observations from the same individual 
and for potential confounders, a GEE model was used for statistical analyses of the 
data presented in Fig. 8.2 (Table 8.2). There was a statistically significant increase in 
positive response after P. falciparum infections for all ELISA’s, which was strongest 
for the whole parasite assay. There also was a statistically significant positive 
association between the prevalence of TRA and the number of infections (Table 8.2).  
 
Table 8.2. The regression coefficient of the number of prior P. falciparum  infections 
as a predictor of seroreactivity or TRA 
 
 N1 Positive response (95% CI)2 P-value 
Whole 
parasite  
102 (296) 
1.30 (0.64--1.96)3
<0.001 
GLURP 102 (296) 0.49 (0.21--0.77)3, 4   0.001 
Pfs48/45  95 (268) 0.40 (0.24--0.57) <0.001 
Pfs230  89 (252) 0.46 (0.25--0.67)3 <0.001 
TRA 76 (161) 0.39 (0.07--0.71) 4   0.016 
 
 
 
 
 
 
 
1Number of individuals (number of measurements)  
2Regression coefficient β (95% confidence interval) 
3Estimate adjusted for age group 
4Estimate adjusted for number of P. vivax infections 
 
Seroprevalence of antibodies against Pfs230 (Fig. 8.3), whole parasite and 
GLURP were consistently higher in adults (data not shown). In adults, 23.8% (10/42) 
of individuals had anti-Pfs230 antibodies prior to exposure, compared to 0% (0/32) in 
children. This higher seroprevalence for adults remained apparent throughout follow-
up. While the intercept of the trend lines was higher in adults (P = 0.001), the slope 
of both lines was not different (P = 0.62), indicating a similar relation between 
number of infections and Pfs230 seroreactivity for adults and children. In the GEE 
models (Table 8.2), the relation between number of infections and whole parasite, 
GLURP and Pfs230 seroreactivity was not different in children and adults. 
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Figure 8.3. The prevalence of Pfs230 seroreactivity as a function of the number of 
prior P. falciparum infections. The prevalence of Pfs230 antibodies is depicted for 
children (shaded bars) and adults (black bars). Error bars indicate the upper limit for 
the 95% confidence interval. The number of observations for children: 0 (n = 32); 1 
(n = 41); 2 (n = 18); 3 (n = 20); 4 (n = 5); >4 infections (n = 3). For adults: 0 (n = 42); 
1 (n = 35); 2 (n = 28); 3 (n = 12); 4 (n = 7); >4 infections (n = 9). Logistic trend lines 
are added to the figures for adults (solid line) and children (dashed line).  
 
 
Discussion 
 
This study shows that sexual stage specific seroreactivity develops after a limited 
number of P. falciparum infections in a cohort of non-immune transmigrants. The 
prevalence of anti-Pfs48/45 and anti-Pfs230 antibodies and functional TRA 
increases with the number of infections experienced.  
Development of sexual stage specific immunity resembles that of immunity 
against asexual stages with similar patterns for acquisition of antibodies against 
GLURP, Pfs230 and Pfs48/45. We found that reactivity against all antigens develops 
quickly after exposure, with seroprevalence increasing with number of infections. In 
line with previous studies, immune response therefore seems to require recent but 
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not necessarily long-term exposure (200-202). Sexual stage specific antibody 
responses seem to be part of the initial immune response, which corroborates 
previous studies in individuals after a primary infection with P. falciparum (210, 211). 
The finding is nevertheless remarkable since it is generally considered that exposure 
to sexual stage parasites is much lower than to asexual parasites. In this study, less 
than one third of the individuals presented with microscopically detectable 
gametocytes on any occasion during the two-year follow-up. This apparent low 
exposure may be due to the poor sensitivity of microscopy for detecting low-density 
gametocytaemia (212), which can contribute substantially to the total exposure to 
gametocytes (213). Sexual stage specific antibodies may be induced by these low 
density gametocytes or by gametocytes that are sequestered in capillary vessels 
(214). The combined possibilities may explain the frequently observed reactivity 
against sexual stage specific antigens in the absence of microscopically detectable 
gametocytes. In addition to these antibody responses, we also frequently observed 
functional TRA without simultaneous or prior detection of gametocytes. Although we 
may have missed some gametocytaemic periods as a result of our fortnightly 
screening we conclude that submicroscopic levels of gametocytaemia do play an 
important role in eliciting sexual stage specific immune responses.  
We found no evidence for age as key determinant for the development of 
immune responses in our population of 6--40 year old transmigrants. Although other 
studies reported an age-dependent acquisition of clinical and parasitic immunity 
(201, 202), we do not find a similar effect for our selected markers of asexual and 
sexual stage specific immunity. The reactivity in ELISA’s was higher in adults but 
could reflect background reactivity due to the presence of cross-reactive antibodies 
reacting with common epitopes (204). We did not detect a difference in the relation 
between exposure to infection and the acquisition of (sexual stage specific) immunity 
for different age groups. 
Our most important finding is the presence of functional TRA in a substantial 
proportion of the individuals increasing with exposure. This has not been shown 
before for P. falciparum, but is analogous to transmission blocking immunity in P. 
vivax, where TRA is more prevalent and efficient after repeated infections (108, 179, 
215). In this study, over one quarter of the individuals experiencing more than four P. 
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falciparum infections showed TRA, i.e. >50% reduction in oocysts numbers. This 
pattern of increasing prevalence of TRA accompanies the occurrence of anti-Pfs230 
and anti-Pfs48/45 antibodies, as previously shown (89, 92, 93, 123, 184). The rapid 
development of TRA and associated antibodies is particularly promising, since 
Pfs230 and Pfs48/45 are considered as candidates for inclusion in future 
transmission-blocking vaccines (210). 
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9.1    TRA in Cameroon 
 
Studies from this thesis (Chapter 6 & 7) show that TRA in populations of 
Cameroon corroborate other studies, which show a range of TRA (5/26 to 4/4 i.e. 19-
100%) in a variety of endemicities (94, 100, 108, 117, 130, 131, 216). Furthermore, 
TRA has been found more prevalent in gametocyte carriers (6-36 years) than in 
randomly selected school children (8-12 years), showing low prevalences of 
gametocytes (93). Little is known about the kinetics and duration of TRA. A small 
study (n=5) with Dutch expatriates who had been living for decades in malaria 
endemic areas, showed that the level of TRA can be high (>85%) and long-lasting 
(up to 80 weeks) (217). These findings prompted us to study the longevity of TRA in 
endemic populations and the possible relationship of the dynamics of TRA with 
transmission intensity. 
We evaluated natural acquisition of TRA in a longitudinal survey in Koundou 
(entomological inoculation rate (EIR) 177 infectious bites per person per year (ibpy), 
as determined the year prior to the survey) and Yaoundé (34 ibpy) in Cameroon 
(149). Gametocyte carriers of 5 to 14 years of age were followed for a year, and the 
SMFA was used for the comparison of sera. Age distributions were comparable in 
both cohorts. Only sera collected after the first documented exposure to 
gametocytes were included in statistical analysis. TRA was slightly elevated in 
Yaoundé and Koundou (median TRA 32% and 37%, respectively) compared to non-
immune sera, and did not correlate with location, age, or gametocytaemia. Both 
cohorts showed no significant associations between TRA and either gametocyte 
density, location, age or time after inclusion over a period of 52 weeks (SAS PROC 
MIXED).  
The inability to show significant differences in TRA may have different causes.  
1) Possibly, there was no effect of age and transmission intensity on TRA. We 
assume, however, that both age and transmission intensity affect TRA. 
Gametocytes, the primary factor causing TRA, are associated with age (99) and 
transmission intensity (Chapter 4), both proxies for P. f exposure. If densities and/or 
prevalences of gametocytes are different between groups, differences in TRA might 
be observed. 
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2) The difference in transmission intensity might be too small to show an effect on 
TRA (34 vs. 177 infectious bites per person per year). At low transmission intensity 
we expect that TRA will be more discriminative (TRA that is close to 0% (most sera, 
no recent gametocyte exposure) or 100% (a few sera, recent exposure to high 
gametocytaemia)). In contrast, high transmission intensity will probably give rise to 
more prevalent, intermediate TRA values (frequent exposure to low 
gametocytaemia).  
3) The chosen age range of five to fourteen years might be too small. The highest 
point prevalence of gametocytes was found in children less than 3-4 years of age in 
both areas. If an area is included with lower transmission intensity, then the 
probability of recruiting subjects with initial TRA will increase.  
4) Probably the essential cause for the low discrimination by TRA is the large 
variability of TRA between experiments, and a more limited variability within 
experiments, as was shown in Chapter 5. In order to reduce variability and to obtain 
more conclusive measurements, we made an effort to improve the SMFA in Chapter 
5 and 6. 
 
9.2   Measurement of TRA by SMFA 
 
The original design of the SMFA suffered from large variation in TRA, which 
compromised comparison of sera. In Chapter 5 we showed that reproducibility of 
TRA was limited if sera were compared between experiments. However, TRA was 
more reproducible within experiments. In addition, reproducibility improved when 
membrane feeds contained relatively high oocyst densities. The variation in TRA 
may primarily depend on variation in 1) control serum, 2) the mosquito vector, and 3) 
sporogonic development. Several measures have been taken in the laboratory to 
standardise serum (pooling of control sera), mosquito (aged 4-6 days) and parasite 
conditions (synchronous culture, prefeeding). Nevertheless, variation remains 
present in oocyst density (1-100/mosquito) and infection rate (approximately 40% of 
all feeds show 100% infected mosquitoes), showing that the SMFA remains 
vulnerable to variation. This may be reduced by adaptation of the methodological 
design to measure TRA. We will successively discuss variation in oocyst density as 
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the basis for TRA, variation in TRA itself, conditions for minimal variation in TRA, and 
possible improvement of the SMFA, and we evaluate different calculation methods 
for transmission reduction. 
 
9.2.1   Variability in oocyst density 
 
The observed large variability (illustrated by the coefficient of variation, 
CV=standard deviation divided by the mean) in oocyst densities is a major cause for 
variability in TRA. Moreover, CV in oocyst density is higher at lower oocyst densities 
and oocyst densities are generally higher in control compared to test feeds. We 
questioned whether TRA varies depending on differences in variability in oocyst 
densities in test and control feeds. The comparable CV for oocyst densities in test 
and control feeds (Fig. 9.1) suggests that TRA is likely not markedly influenced by 
differences in variability of oocyst densities with test and control sera. 
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Figure 9.1: The relationship between coefficients of variation and average oocyst 
density per mosquito with A. control and B. experimental sera in pooled SMFAs. 
Oocyst densities were arithmetically averaged, including experimental feeds with 
between 17and 20 mosquitoes per feed. The curves were derived from power 
regression of oocyst densities and the coefficients of variation. The coefficient of 
variation (CV = standard deviation /mean) = a x (average oocyst density)b, with a = 
1.84 and b = -0.24 for test sera; and a = 1.93 and b = -0.25 for control sera.  
 
The CV of oocyst numbers declined with increasing oocyst density, as was also 
demonstrated in a previous P. berghei study (164). In P. falciparum we found a high 
CV at low oocyst densities (Chapter 5; Fig 9.1; Table 9.1). Clustering of feeds 
according to oocyst density shows that lowest oocyst density (cluster 1: on average 
2.7 oocysts per mosquito) has a more than threefold higher CV than cluster 5 with on 
average 116 oocysts/mosquito. Thus, the CV for oocyst densities and possibly the 
CV for TRA can be considerably reduced in experiments with high compared to low 
oocyst densities. This can be reached by feeding mosquitoes with large numbers of 
gametocytes. Furthermore, oocyst variability can be limited by feeding larger 
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numbers of mosquitoes, which will yield more precise TRA values and lower 
standard deviations.  
 
Table 9.1:. Oocyst density, variability and prevalence of non-infected mosquitoes in 
clusters of feeds based on increasing average oocyst densities per mosquito midgut 
in control feeds. All 22 negative feeds were excluded from analysis. 
Oocyst density2 CV3
Cluster 
 
 
N1
Mean4 95%CI5 Mean4 95%CI 
% Mosquitoes 
uninfected 
1 1636 2.72 2.61, 2.83 1.94 1.70, 2.17 51.4 
2 1678 15.0 14.8, 15.2 1.10 1.03, 1.94 18.5 
3 1662 31.7 31.5, 32.0 0.80 0.74, 0.87 8.7 
4 1658 58.8 58.3, 59.3 0.74 0.70, 0.78 5.8 
5 1703 116.4 114.8, 118.0 0.56 0.54, 0.59 2.2 
 
1All mosquito feeds from SMFAs performed in a period of three years are clustered according to 
average oocyst density, excluding negative mosquito feeds. N equals the number of mosquitoes per 
feed cluster. Every feed forms 1 datum with an arithmetic mean (AM) oocyst density and a coefficient of 
variation (CV) 
2 based on the AM oocyst densities for all feeds per feed cluster 
3 based on the average coefficient of variation in oocyst density for all feeds per feed cluster 
4 AM of the AM oocyst densities (or CV) per feed cluster  
5 CI: Confidence intervals 
 
9.2.2  Variability in TRA 
 
We investigated whether variability of TRA test results could be reduced, by 
simulation with historical mosquito feeds. Feed data were selected to obtain 
assumed TRA values of about 50%, 75% and 90% (Fig 9.2). The confidence limits 
for TRA were narrowest at high oocyst densities, at all three simulated TRA values. 
Furthermore, the confidence limits for TRA were wide at 50% TRA, narrower at 75% 
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TRA and even narrower at 90% TRA. Thus, variation in TRA values was limited at 
high oocyst densities and at high TRA values. 
Calculated TRA values (the adjusted ratio of oocyst densities in control and 
experimental feeds, using the formula in Chapter 5) were slightly higher and 
approached the TRA estimates (the non-adjusted ratio: TRA 50, 75 or 90%) at the 
higher oocyst densities. Furthermore, high TRA (90%) can be distinguished from 
TRA50%, at all simulated oocyst densities. High and intermediate TRA (75%) can be 
distinguished from each other in experiments with a minimum of approximately  fifty 
oocysts on average per control mosquito. Most human sera show intermediate TRA 
(20-80%) with large variation at all simulated oocyst densities. Therefore, TRA is 
generally not discriminative for individual human sera. We recommend that groups of 
sera, rather than individual sera are compared.    
 
9.2.2 Conditions for minimal variability in TRA 
 
In Chapter 5 we showed that the reproducibility of TRA was fairly low, especially 
in experiments with either low or high control oocyst densities (<20 or >45 
oocysts/mosquito). Low reproducibility of TRA at low oocyst densities can be 
explained by the relatively large variation (CV) in oocyst densities and TRA (9.2.1). 
Despite lower CV, TRA was more variable at high oocyst densities, which is more 
difficult to explain, but is related to selection bias of the control feeds. This bias 
originated from selection for high oocyst densities in control feeds, while selection in 
experimental feeds was omitted. Experiments were considered not valid when 
control feeds showed low oocyst densities, but all oocyst densities were accepted 
from the experimental feeds. Therefore, oocyst densities in control feeds were higher 
on average than in experimental feeds due to random variation. This implies that 
TRA was somewhat overestimated if experiments were selected based upon oocyst 
densities in control feeds. Thus, the higher the threshold for the selection of oocyst 
densities in control feeds, the larger the selection bias. We, therefore, recommend 
limiting the selection bias by using a low threshold for oocyst densities, and to limit 
variation in TRA by extending the number of mosquitoes per feed. Another option to 
prevent the selection bias is to select experiments with high gametocyte densities  
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Figure 9.2: [Legend, see next page]. 
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Figure 9.2: Variation in TRA in relation to oocyst density in control feeds: median 
TRA (closed circles) and 90% confidence intervals (open circles). TRA values were 
simulated using oocyst distributions from retrospective mosquito feeds. Simulated 
TRA of 90% (A), 75% (B) and 50% (C). Experimental feeds were selected with 20 
mosquitoes and average oocyst densities of 156 (control feed, very high oocyst 
density), 16, 39 and 76; 50 (control feed, intermediate oocyst density), 5, 13 and 25; 
20 (control feed, high oocyst density), 2, 5 and 10; 2.7 (control feed, low oocyst 
density), 0.3, 0.7 and 1.3, in order to obtain estimated 90%, 75% and 50% TRA 
respectively. Median TRA values and 90% CI were calculated, using the range value 
as control and the other values as proxy for test feeds. Variation (the wideness of the 
90% CI) was largest at 2.7 oocysts in the control feed (the lowest oocyst density) 
and smallest at 156 oocysts in the control feed (the highest density), for each of the 
simulated TRA values.  
 
(giving rise to unselected high oocyst densities) instead of experiments with high 
oocyst densities. 
Preliminary data in Chapter 6 based upon gametocyte densities between 80 and 
800/μl, suggest that, within this range, TRA depends on gametocyte density. 
Therefore, SMFA with low gametocyte densities, i.e. more similar to gametocyte 
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densities found in the field (on average 20-40/μl blood) (189, 190), may yield higher 
TRA values. In this case, the number of mosquitoes for dissection has to be 
increased to, for example, forty mosquitoes per feed. In the current SMFA design, 
membrane feeds contain 800-1600 gametocytes per μl and yield on average over 40 
oocysts per mosquito. Membrane feeds with 20-40 gametocytes per μl, i.e. a forty-
fold decrease, will give rise to an estimated one oocyst per mosquito. The 
prevalence of infected mosquitoes with one oocyst per mosquito varied between 15-
60% in our database, which may depend on number and quality of engorged 
gametocytes. A feed of forty mosquitoes will result in at least six positive mosquitoes 
per feed. In addition, we found that the minimum requirement for mature 
gametocytes to be infectious to mosquitoes varies between 0.4 and 0.8 per μl blood 
(approximately one to two per mosquito), using 100 and fifty mosquitoes respectively 
(218). This suggests that the proposed experimental set up with forty mosquitoes per 
dissection can be used for the assessment of TRA. 
To limit TRA variability this experimental set up will have to be accompanied by 
some changes in the feeding procedures. The number of fully fed mosquitoes will 
have to be doubled. In the current feeding assay more than fifty mosquitoes are fed, 
of which more than 80% are fully engorged (prerequisite), and only twenty 
mosquitoes are dissected for oocyst counts. Mortality rate of mosquitoes in the 
seven days after feeding is negligible. Therefore, the size of the feeder and the 
volume of the gametocyte suspension can remain the same. However, twice as 
many fully fed mosquitoes will have to be dissected and analysed.  
 
9.2.4  Suggestions for improvement of SMFA  
 
In Chapter 5 we recommended direct comparison of sera within experiments. 
This is easy to establish in small sets of test serum (18 or less sera), but larger 
serum sets need precise planning for proper application of statistical analysis. Sera 
should be grouped according to the research question. All different test groups 
should ideally be represented in any SMFA experiment with at least one serum. Test 
groups can then be compared by repeated measurement analysis considering the 
individual SMFA experiment as a random variable. This would account for inter-
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experimental variability. Planning of a series of SMFA experiments with for example 
fifty sera in two groups of 25 sera each is shown in Figure 9.3. In each SMFA two 
control feeds are included. Outcome for serum groups A and B are compared in 
each SMFA. 
 
25 subjects  
Group A 
25 subjects  
Group B 
SMFA 1 
A1 A2 A3 A4 A5 A6 A7 A8 A9 B1 B2 B3 B4 B5 B6 B7 B8 B9 C1 C2
 
Etc. 
 
Figure 9.3: Planning of a series of 50 experimental feeds in the SMFA, considering 
two different groups (A and B), controlsera C1 and C2, 20 feeders per experiment. 
Sera should have random places in the feeders (not shown here, in order to facilitate 
the overview). 
 
Comparison of large numbers of subjects per group may further complicate 
SMFA design. Most important is that the number of sera per group are evenly 
distributed over the SMFA experiments. Longitudinal studies with large numbers of 
sera require a different SMFA design. Experimental design should ideally account for 
both the time series of sera and the covariate. We recommend including full time 
series of sera per individual within individual SMFAs, in combined test samples 
(Figure 9.4). Subgroups should be accounted for by comparing the combined test 
samples from different subgroups within experiments. If the number of sera per 
individuals does not allow for testing all subgroups within one experiment, subgroups 
should be allocated at random over the experiments. Breaking time series of sera 
should be avoided.  
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25 subjects group A T1-3 25 subjects group B T1-3 
SMFA 1 
A1 
T1 
A1 
T2 
A1 
T3 
B1 
T1 
B1 
T2 
B1 
T3 
A2 
T1 
A2 
T2
A2 
T3
B2 
T1
B2 
T2
B2 
T3
A3 
T1
A3 
T2
A3 
T3
B3 
T1
B3 
T2 
B3 
T3 C1 C2
 
Etc. 
 
Figure 9.4: Planning of a series of 150 experimental feeds in the SMFA, considering 
three time points per individual and two different groups. Sera should have random 
places in the feeders (not shown here, in order to facilitate the overview). 
 
9.2.5 Evaluation of different calculation methods for transmission reduction 
 
Three continuous measures (TRA (Chapter 5, 6), TR Effect Size (Chapter 7) and 
Lensen Rcont (136)) and three categorical measures (TRA50% (Chapter 8), TR 
prevalence (Chapter 7) and Lensen Rcat (136)) for transmission reduction have been 
discussed. Here, we compare reproducibility and correlation of those measures, 
using replicate feeds of 158 sera. If sera were tested more than twice, only the first 
two feeds for every serum were included in analysis. Spearman’s (non parametric) r 
correlation coefficients were determined for continuous outcomes. Correlation 
coefficients for TRA (0.47 P<0.001), TR Effect Size (0.50, P<0.001) and Lensen Rcont 
(0.49, P<0.001) were all similar. Prevalence parameters were evaluated by 
comparing the first and the second assessment, and determining whether positive 
outcome concerns the same individuals in both assessments. Prevalences that were  
firstly and secondly assessed for TRA50%, were 56 and 58% (χ2 = 26.1); for TR 48 
and 56% (χ2 = 17.3); and for Lensen Rcat 58 and 65% (χ2 = 21.1) (P values <0.001), 
respectively. Double positive outcomes in repeated experiments were evaluated with 
formula 9.1 for reproducibility (Rep). Rep values were 0.42 for TRA50%, 0.35 for TR 
prevalence and 0.42 for Lensen Rcat. The combination of both analyses suggests 
that with respect to the evaluated dichotomous transmission reducing measures the 
probability of reproducing positive results is the highest for TRA50%. 
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Observed – expected double positive outcome  
Rep =  _____________________________________      Formula 9.1 
Expected – minimum double positive outcome  
  
Since like the categorical measures, the different continuous measures were 
similarly reproduced, a preference can be made for the clearest method. A special 
case is Lensen’s R measure, defined by the ratio of log transformed oocyst densities 
in test and control feeds (136). For instance, a 90% reduction of 100 to 10 oocysts 
corresponds with R 50%. Because of the consistent underestimate of R, the R 
measure is not taken into account. TRA (i.e. the percentage of oocysts reduced by 
serum, using arithmetic means of oocysts densities) is easier to interpret than TR 
Effect Size (i.e. the standardized difference between mean oocyst densities in 
control and experimental feeds). We therefore recommend TRA as the continuous 
measure for transmission reduction. The recommended dichotomous measure for 
transmission reduction is TRA50%, considering all sera with TRA values of at least 
50% as TRA50% positive. 
We applied TRA and TRA50% for the analysis of TRA in migrants in Indonesia 
(Chapter 8), using 20 mosquitoes per feed, comparing sera within and between 
experiments. TRA50% showed a weak positive association with the number of 
malaria infections, whilst we were not able to show an association of continuous TRA 
with exposure experience. Compliance with recommended comparison within 
SMFAs and increase of mosquito numbers per feed would likely ameliorate the 
discriminative power of both TRA and TRA50%. 
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 Conclusions and recommendations 
 
The described limitations upon reproducibility of quantitative TRA makes it clear 
that the SMFA needs improvement. We made the following recommendations based 
upon the main findings of this thesis. 
The assessment of TRA by the SMFA can be improved by a number of changes. 
Feeding less gametocytes, preferably at densities generally found in nature, can 
counteract the underestimate of TRA in the current setting. The resulting increase in 
variability in TRA can be compensated by increasing the number of mosquitoes per 
feed, and by pooling the mosquitoes in the two control feeds. The selection bias as a 
result of a high threshold for oocyst densities in control feeds can be reduced by 
decreasing such threshold. In practice, these recommendations can be combined 
with using low numbers of gametocytes (twenty to forty per μl) which are more 
reflective of natural consitions and, consequently, forty mosquitoes per feed. 
 
We further recommend  
 
1 to use TRA as a continuous measure and TRA50% as a categorical measure 
for transmission reduction. 
2 to compare TRA within experiments  
3 to evaluate the variability in TRA under the recommended circumstances by 
repeated feedings on a large number of individual endemic sera  
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Summary 
 
Human malaria is a parasitic disease, which causes over 200 million clinical 
cases and more than one million deaths per year. Most cases occur in children aged 
below five and the most affected continent is Africa with about 90% of all cases. 
Malaria is spread by sexual forms of Plasmodium parasites (gametocytes), which are 
transmitted by anopheline mosquitoes from infected to susceptible humans. Human 
subjects in endemic areas may naturally acquire immunity against the various 
parasite stages involved in transmission. This TRA can be assessed by a laboratory 
assay, the SMFA, or a comparable field based bioassay, the DMFA.  
The SMFA mimics natural infection by feeding mosquitoes with a mixture of 
human red blood cells, infected with cultured P. falciparum gametocytes, and test or 
control serum. Test serum is collected from malaria exposed human subjects, and 
control serum from non-immune Dutch subjects. In the DMFA, blood from 
gametocytes is fed to mosquitoes in the presence of autologous (test) or control 
serum. Fertilisation of male and female gametes takes place in the mosquito midgut, 
in both SMFA and DMFA (and in natural infection). As a result oocysts appear on the 
mosquito midgut wall. Transmission reducing antibodies in test serum can interrupt 
this process and reduce oocyst numbers. TRA is defined as the relative difference in 
oocyst numbers between control and test feeds. 
The first objective of this thesis was to study the association between TRA and 
transmission intensity in local populations in Cameroon (Chapter 2-4). Transmission 
intensity was determined in a selected field site, Dakar quarter in the capital 
Yaoundé, during one-year follow up (Chapter 2). A. gambiae and A. funestus were 
the main vectors and the entomological inoculation rate (EIR) was 34 infectious bites 
per man per year (ibpy). A. gambiae (EIR = 30 ibpy) contributed more to 
transmission than A. funestus (EIR = 4 ibpy). The transmission intensity in Yaoundé 
was about five times lower than at the comparable study site in rural Koundou 
(previously reported EIR of 177 ibpy). 
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The average annual parasite prevalence in Yaoundé was 35% for P. falciparum 
asexual parasites and 4.4% for gametocytes (Chapter 3). The prevalences of high 
parasitaemias (>400 parasites/μl blood) and gametocytes showed seasonal and 
age-dependent variation. Children of zero to fifteen years represented 83% of 
gametocyte carriers, and they dominate the potential infectious reservoir in Yaoundé. 
TRA was measured by DMFA and compared with age, gametocyte density and 
transmission intensity in Chapter 4. Peak prevalence of gametocytes occurred in a 
lower age group in the area with the higher transmission intensity (the region around 
Koundou). The probability that gametocyte carriers showed TRA was 4.6 fold higher 
in the Koundou area than in Dakar. In addition, there was a trend towards higher 
TRA values in individuals with higher gametocytaemias. A relationship between TRA 
(prevalence or level) and age could not be observed. TRA results, however, were 
subject to poor reproducibility.  
The second objective of the thesis was to evaluate and possibly improve the 
SMFA methodology (Chapter 5). An extensive retrospective analysis of the data set 
comprising 307 serum samples (tested up to six times in 201 feeding experiments) 
showed that TRA values in repeated measurements had a substantially variable 
outcome for individual sera. However, TRA was more often reproducible than would 
have been expected by chance alone. In addition, as a quantitative measure TRA 
was better reproduced than the qualitative SMFA read-out that had been used for 
many years as a gold standard. The variability in TRA was larger between 
experiments than within experiments. Therefore, sera are better compared within 
rather than between experiments.  
In Chapter 6, reproducibility of TRA was further studied by evaulating repeated 
measurements with increasing concentrations of transmission blocking antibodies. 
TRA associated strongly with concentration of anti-sexual stage (anti-Pfs25, anti-
Pfs48/45) antibodies. Gametocyte density was a significant cofactor in this 
association. TRA levels were higher if gametocyte suspensions were serially diluted 
at each antibody concentration tested. These results further support the use of the 
applied calculation methodology for TRA assessed by a modified SMFA as a 
quantitative measure for reduction of transmission. 
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In Chapter 7, the existence of transmission enhancement (TE) was studied in a 
set of human sera from three different geographic areas. The presence of both TE 
and TRA were demonstrated in these sera. The prevalence of TE (7%) by human 
sera was much lower than TRA (48%) and its effect generally weaker. Furthermore, 
only TRA (and not TE) correlated with sexual stage antibodies. Thus, TE exists in 
endemic sera, but its effect is limited compared to the effect of TRA. 
In Chapter 8, the improved methodology for SMFA was applied for the 
assessment of natural acquisition of TRA in non-immune transmigrants in malaria 
endemic Papua, Indonesia. TRA and anti-sexual stage antibodies (anti-Pfs230 and 
anti-Pfs48/45) increased after one to four infections already. TRA is thus rapidly 
acquired upon exposure to infection.  
In the discussion (Chapter 9), the conditions for minimal variability in the SMFA 
were further discussed and suggestions for improved methodology presented. These 
include 1) comparison of serum samples within experiments, 2) reduction of the 
number of gametocytes (20-40/μl), and 3) increase of the number of mosquitoes per 
test sample for assessment of oocysts (from 20 to about 40). In this manner, the 
SMFA will more closely reflect natural conditions. We expect that the adapted 
methods will enable more detailed studies on the development and maintenance of 
TRA in endemic populations. 
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Samenvatting  
 
Humane malaria is een parasitaire ziekte, die meer dan 200 miljoen ziekte- en 
meer dan één miljoen sterfgevallen per jaar veroorzaakt, met name in kinderen 
onder vijf jaar en voornamelijk in Afrika. Malaria wordt verspreid in de bevolking door 
seksuele vormen van Plasmodium parasieten (gametocyten), die van besmette naar 
vatbare mensen worden overgedragen door Anopheles muggen (transmissie). 
Mensen die leven in gebieden waar malaria voorkomt, kunnen natuurlijke immuniteit 
ontwikkelen tegen stadia van de parasiet, die betrokken zijn bij transmissie. Deze 
transmissie reducerende activiteit (TRA) kan worden bepaald met een 
laboratoriumtest, de Standaard Membraan Voeding Test (SMFA), of met een 
vergelijkbare biologische test in het veld, de Directe Membraan Voeding Test 
(DMFA). 
De SMFA bootst natuurlijke infectie na, door muggen te voeden met een 
mengsel van menselijke rode bloedcellen, die zijn geïnfecteerd met gekweekte P. 
falciparum gametocyten en test- of controle-serum. Testserum is afkomstig van 
mensen die blootgesteld zijn geweest aan malaria, en controle-serum van niet-
immune Nederlandse bloeddonors. In de DMFA wordt bloed van 
gametocytendragers in de aanwezigheid van eigen (test-) of controle-serum gevoed 
aan muggen. In de muggenmaag barsten de rode bloedcellen open, komen 
mannelijke en vrouwelijke gameten vrij en vindt bevruchting plaats. Dat gebeurt in de 
SMFA en de DMFA (en bij natuurlijke infectie). Na verloop van tijd (vanaf twee 
dagen na infectie) kunnen oöcysten verschijnen in de wand van de muggenmaag. 
Transmissie blokkerende antilichamen in test serum kunnen dit proces onderbreken, 
waardoor het aantal oöcysten vermindert. TRA wordt gedefinieerd als het relatieve 
verschil in oöcysten aantal tussen controle en testvoedingen.  
De eerste doelstelling van dit proefschrift was de relatie van TRA met transmissie 
intensiteit te onderzoeken in de lokale bevolking in Kameroen (Hoofdstuk 2-4). De 
transmissie intensiteit werd gedurende een jaar bepaald in een geselecteerd 
onderzoeksgebied, de wijk Dakar in de hoofdstad van Kameroen, Yaoundé 
(Hoofdstuk 2). A. gambiae en A. funestus waren de belangrijkste muggensoorten
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voor de transmissie van malaria in Dakar. De transmissie intensiteit werd bepaald op 
34 besmettelijke beten per mens per jaar (besmette beten per 
persoon per jaar, bbpj). A. gambiae (30 bbpj) droeg meer bij aan transmissie dan A. 
funestus (4 bbpj). De transmissie intensiteit in Yaoundé was ongeveer vijf keer lager 
dan in het tweede onderzoeksgebied, het dorp Koundou (eerder gerapporteerde 
transmissie intensiteit van 177 bbpj).  
Jaarlijks had gemiddeld 35% van de mensen in Yaoundé aseksuele P. 
falciparum parasieten en gemiddeld 4,4% had gametocyten (Hoofdstuk 3). De 
aanwezigheid van hoge parasitaemie (>400 parasieten / μl bloed) en van 
gametocyten was seizoensgebonden en leeftijdsafhankelijk. De leeftijdsgroep van 0-
15 jaar vertegenwoordigde 83% van de gametocytendragers. Kinderen zijn daarmee 
verreweg belangrijkste bron voor malaria overdracht in dit gebied. 
TRA werd bepaald met de DMFA en werd vergeleken met leeftijd, 
gametocytendichtheid en transmissie intensiteit in Hoofdstuk 4. De gemiddelde 
leeftijd van gametocytendragers was lager in het gebied met de hogere transmissie 
intensiteit (de regio rond Koundou). De frequentie van TRA onder 
gametocytendragers was 4.6 maal hoger in het gebied rond Koundou vergeleken 
met Dakar. Bovendien was er een tendens voor hogere TRA waarden in individuen 
met hogere aantallen gametocyten in het bloed. Een relatie tussen TRA en leeftijd 
kon niet worden vastgesteld. Hoe dan ook, TRA resultaten waren onderhevig aan 
matige reproduceerbaarheid.  
De tweede doelstelling van dit proefschrift was de evaluatie en mogelijke 
verbetering van de SMFA methodologie (Hoofdstuk 5). Een uitgebreide analyse van 
eerder verzamelde data van 307 testsera (die tot zes keer per serum werden getest 
in 201 experimenten) lieten een aanzienlijke variabiliteit zien van TRA voor 
individuele sera. Niettemin kwamen vergelijkbare waarden van TRA vaker voor bij 
herhaalde metingen dan zou worden verwacht op grond van toeval (Hoofdstuk 5). 
Daarnaast was de kwantitatieve TRA beter reproduceerbaar dan het kwalitatieve 
SMFA uitleessysteem dat jarenlang werd gebruikt als gouden standaard. Verder was 
de variabiliteit in TRA groter tussen dan binnen experimenten. Sera kunnen daarom 
beter binnen dan tussen experimenten worden vergeleken. 
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In Hoofdstuk 6 werd de reproduceerbaarheid van TRA verder bestudeerd in 
herhaalde metingen, door vergelijking van oplopende concentraties van transmissie 
blokkerende antilichamen. TRA was sterk gerelateerd met concentraties van 
antilichamen tegen seksuele stadia (anti-Pfs25, anti-Pfs48/45). Daarbij was het 
aantal gevoede gametocyten een belangrijke factor. TRA waarden waren hoger als 
gametocyten werden verdund, bij elke geteste antilichaamconcentratie. Deze 
resultaten ondersteunen het gebruik van de toegepaste berekeningsmethode voor 
TRA (zoals bepaald in de aangepaste SMFA) als kwantitatieve maat voor 
transmissie reductie. 
In Hoofdstuk 7 werd het bestaan van transmissieversterking (TE) bestudeerd in 
een groep menselijke sera uit drie verschillende geografische gebieden. Zowel TE 
als TRA werd aangetoond in deze sera. TE (7%) kwam veel minder voor in 
menselijke sera dan TRA (48%), en het effect van TE was over het algemeen 
zwakker. Verder correleerde slechts TRA (en niet TE) met seksueel stadium 
antilichamen. TE bestaat dus in sera uit malaria gebieden, maar het effect is beperkt 
vergeleken met het effect van TRA. 
In Hoofdstuk 8 werd de verbeterde methodologie voor SMFA toegepast voor de 
beoordeling van de ontwikkeling van TRA in transmigranten in de Papoea provincie 
in Indonesië. De transmigranten waren niet eerder blootgesteld geweest aan 
malaria, terwijl in de Papoea provincie veel malaria voorkomt. TRA en seksueel 
stadium antilichamen (anti-Pfs230 en anti-Pfs48/45) namen al na één tot vier P. 
falciparum infecties toe. TRA wordt dus snel verkregen na blootstelling aan infectie. 
In de discussie (Hoofdstuk 9) werden de voorwaarden voor minimale variabiliteit 
in TRA besproken en suggesties voor verbetering van SMFA gepresenteerd. Deze 
omvatten 1) vergelijking van serum monsters binnen experimenten, 2) vermindering 
van het aantal gametocyten (twintig tot veertig per μl), en 3) verhoging van het aantal 
muggen per voeding (van twintig tot meer dan veertig). Zo zou de SMFA beter 
overeenkomen met natuurlijke transmissie. We verwachten dat de aangepaste 
methode meer gedetailleerde studies mogelijk maakt, met name naar de 
ontwikkeling en het verloop van TRA in gebieden waar malaria veel voorkomt.
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